



Published in final edited form as:

Cond Med. 2018 June ; 1(4): 151–166.

A Dual Role for Hyperbaric Oxygen in Stroke Neuroprotection: Preconditioning of the Brain and Stem Cells

Grant M. Liska, Trenton Lippert, Eleonora Russo, Norton Nieves, and Cesar V. Borlongan¹

¹Center of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair, University of South Florida Morsani College of Medicine, Tampa, FL

Abstract

Stroke continues to be an extremely prevalent disease and poses a great challenge in developing safe and effective therapeutic options. Hyperbaric oxygen therapy (HBOT) has demonstrated significant pre-clinical effectiveness for the treatment of acute ischemic stroke, and limited potential in treating chronic neurological deficits. Reported benefits include reductions in oxidative stress, inflammation, neural apoptosis, and improved physiological metrics such as edema and oxygen perfusion, all of which contribute to improved functional recovery. This pre-clinical evidence has failed to translate into an effective evidence-based therapy, however, due in large part to significant inconsistencies in treatment protocols and design of clinical studies. While the medical community works to standardize clinical protocols in an effort to advance HBOT for acute stroke, pre-clinical investigations continue to probe novel applications of HBOT in an effort to optimize stroke neuroprotection. One such promising strategy is HBOT preconditioning. Based upon the premise of mild oxidative stress priming the brain for tolerating the full-blown oxidative stress inherent in stroke, HBOT preconditioning has displayed extensive efficacy. Here, we first review the pre-clinical and clinical evidence supporting HBOT delivery following ischemic stroke and then discuss the scientific basis for HBOT preconditioning as a neuroprotective strategy. Finally, we propose the innovative concept of stem cell preconditioning, in tandem with brain preconditioning, as a promising regenerative pathway for maximizing the application of HBOT for ischemic stroke treatment.

Keywords

preconditioning; ischemia; neuroprotection; neurodegeneration; cell therapy; regenerative medicine

1.0 Introduction

Stroke is defined as a sudden loss of blood supply to brain tissue resulting from either hemorrhagic or ischemic pathology causing severe neurological deficit (Jickling et al., 2014). In the United States, stroke is the fifth leading cause of death, with an occurrence rate of roughly 800,000 per year (George et al., 2017). Stroke can be broadly classified into

Correspondence should be addressed to Dr. Cesar V. Borlongan (cborlong@health.usf.edu).

Conflicts of Interest: The authors declare that they have no conflicts of interest.

hemorrhagic and ischemic stroke, with the latter accounting for 87% of all strokes (Go et al., 2014). Hemorrhagic stroke is overwhelmingly fatal, and thus provides a smaller therapeutic opportunity. Thrombolytic tissue plasminogen activator (TPA) is currently the only Food and Drug Administration (FDA)-approved intervention available for ischemic stroke, and is approved for use only within the first 4.5 hours following onset; delivery beyond this window is associated with a stark increased occurrence of severe hemorrhagic transformation (Knecht et al., 2017). Someone in the U.S suffers from stroke every 4 seconds, and with limited therapeutic options, new and effective stroke treatments are an urgent necessity.

Ischemic stroke pathology is characterized by abrupt blood vessel occlusion, causing ischemic damage to the area of the brain supplied by the occluded artery. During the acute phase, this primary anoxic environment induces a cascade of excitotoxicity, oxidative stress, and microglial activation throughout the infarcted region, resulting in extensive neural death (Stonesifer et al., 2017). Reactive oxygen species (ROS) weaken vasculature and create ionic imbalances, which lead to an abnormal increase of water movement into the intracellular space, resulting in edema (Stokum et al., 2016). In the subacute phase, cytokines, chemokines, and matrix metalloproteases (MMPs) are released, contributing to neuroinflammation (Lakhan et al., 2009). Elevated expression of MMPs increases blood-brain barrier (BBB) permeability, allowing migratory waves of leukocytes into the infarct area and exacerbating inflammatory activity (Lakhan et al., 2009). Multiple cell phenotypes which comprise the neurovascular unit (Lo et al., 2009) within the penumbra – the area of brain tissue surrounding the infarcted core – are susceptible to the abovementioned pathological mechanisms as well. These cells, however, are salvageable, and their protection is of great interest in rescuing the motor and cognitive functional deficits which follow stroke (Wetterling et al., 2016).

Hyperbaric oxygen treatment (HBOT) is a non-invasive therapy performed in a pressurized chamber where pure oxygen is administered at above-normal atmospheric pressure. This condition improves oxygenation from lungs to systemic organs, enhancing biomolecular processes specifically in ischemic conditions (Thom, 2011). Under increased oxygenation in the infarct core and penumbra, HBOT can reduce secondary brain injury effects such as apoptotic pathway initiation, oxidative stress, and rampant inflammation (Ostrowski et al., 2017). HBOT has shown promising restorative effects in a wide range of pathological contexts, including within TBI, SCI, stroke and other non-neurological maladies such as carbon monoxide poisoning, gangrene, and arterial gas embolism (Baratz-Goldstein et al., 2017). Among the neurological pathologies, in general, few effective treatment options are offered and severe debilitation and/or death are common outcomes. Current HBOT experimental studies have demonstrated improvement in facilitation of cerebral oxygenation, metabolism, angiogenesis, and reduction in inflammation in stroke and non-stroke disease states (Zhai et al., 2016). HBOT studies aim to effectively attenuate ischemic-related damage, as well as utilize various other mechanisms, all in an effort to improve the quality of life of affected patients. Here, we review the current status of HBOT for ischemic stroke, present scientific support and rationale for HBOT preconditioning in the stroke brain, and finally propose HBOT priming of stem cell transplantation as a promising and novel paradigm for stroke therapy.

2.0 HBOT in Ischemic Stroke: Potential Benefits and Limitations

Early investigations began 50 years ago on the results of hyperoxia following stroke; however, HBOT was viewed as more dangerous than beneficial, and the application of its therapeutic value was abandoned. In the last 20 years, this tapered view of HBOT has shifted towards a favorable assessment of its potential application in stroke as further research has revealed the ability of HBOT to reduce the severity of infarct volume if administered during the reperfusion window (Hu et al., 2017). This, however, creates a very limited opportunity for effective treatment as determination of reperfusion will require imaging modalities to inform the appropriate course of action, and by the time such assessment is completed the narrow effective timeframe for HBOT has likely passed (Chang et al., 2000). Other studies showed that delayed HBOT past the effective window of treatment resulted in worse outcomes versus the normobaric groups, potentially due to the role of ROS in glutamate-induced excitotoxic cell death (Singhal et al., 2002). Thus, indiscriminate use of HBOT is inadvisable, as treatment with excess oxygen can cause additional harm, such as obstructive pulmonary disease (Singhal et al., 2002).

Normobaric oxygen has also been critically evaluated as a potential treatment for stroke, with therapeutic efficacy being both reported and refuted (Padma et al., 2010; Singhal et al., 2005; Shi et al., 2016). While normobaric oxygen therapy does increase dissolved O₂ available within the blood, it has not been demonstrated to exert other neuroprotective effects which are central to HBOT effectiveness both post- and pre-stroke, and is thus less intriguing when exploring preconditioning paradigms (Padma et al., 2010; Singhal et al., 2005; Shi et al., 2016).

To date, two primary methods of utilizing HBOT have been employed -- post-stroke and preconditioning. Following stroke, the goal of HBOT is to induce hyperoxia during the ischemic and reperfusion periods or expose the subject to repeated treatments once past the initial early treatment window (Zhai et al., 2016). Current preconditioning treatments focus on exposing the individual (albeit endogenous cells) to a mild stressor, therefore increasing tolerance to future stressors (Godman et al., 2010).

2.1 Preclinical functional outcomes of post-stroke HBOT

A typical HBOT treatment is conducted at 2.5 atmospheres (ATM) for a period of 60–90 minutes (Ostrowski et al., 2016), although protocols vary outside of this framework. If the pressure exceeds 2.5 ATM during HBOT, oxygen toxicity as well as increased oxidative stress can present throughout the body. Moreover, as the pressure increases above the recommended level, the risk of seizure activity increases drastically (Zhai et al., 2016). The primary goal of acute HBOT treatment is to increase oxygen levels in the ischemic region during stroke occlusion, in pursuit of minimizing hypoxic damage. Once past the initial treatment window, repeated HBOT treatments over several days have been shown to promote stimulation of endogenous repair processes (Wang et al., 2008).

The potency of HBOT appears to wane significantly as treatment initiation is delayed. Following an ischemic event, several studies have demonstrated effectiveness of HBOT when administered within 30 to 60 minutes of stroke, as evidenced by reduced infarct

volume and improved behavioral scores (Chang et al., 2000; Hu et al., 2017). While useful as a proof-of-concept, this highly acute treatment timeframe provides little translational value. Importantly, though, investigations have found effectiveness with HBOT at less restrictive time points, such as HBOT (2.5 ATA for 2 hours) at 6 hours after reperfusion (Yin et al., 2003), and HBOT (3 ATA, 1 hour) at 3 and 6, but not 12, hours after reperfusion (Lou et al., 2004). While single-session HBOT has been reported as effective when initiated up to 18 hours (Xue et al., 2008) and 48 hours (Mu et al., 2013) after stroke, therapeutic effects with HBOT at more extended timepoints (i.e. 12+ hours after reperfusion) will generally necessitate more extensive and tailored treatment protocols. Delayed repeat treatment, with HBOT (2.5 ATA, 2 hours) initiated at 6 or 24 hours following stroke and delivered for 6 consecutive days, resulted in amelioration of infarct size and neurological deficits (Yin et al., 2005). Another report found significant chronic improvement in behavioral and histological outcomes following MCAO when exposed to an aggressive regimen of 15 HBOT sessions (2.5 ATA, 90 min) 5 times per week over 3 weeks, initiated 24 hours after stroke (Lee et al., 2013). Scarce evidence exists for the effectiveness of HBOT when initiated more than 48 hours post-stroke; a single study using a severe model of focal ischemia found that one session of HBOT (3 ATA, 1 hour) exhibited significant neuroprotective effects when delivered up to 72 hours post-stroke (Veltkamp et al., 2005).

2.2 Clinical results of HBOT in stroke

There have been only a handful of randomized controlled clinical trials involving HBOT to date, resulting in inconclusive results (Bennett et al., 2014). Many different factors likely contribute to the varying clinical results, including the unstable clinical status of acute stroke patients, preventing them from receiving HBOT during the early effective treatment window of 3–5 hours in humans (Sanchez, 2013). Moreover, wide variations in treatment protocols and stage of patient enrollment (i.e. more acute, sub-acute and chronic) likely inhibit the ability to draw reliable conclusions and compare outcomes across trials. Nonetheless, clinical success for HBOT has been achieved; for example, the use of HBOT has been shown to reduce levels of cerebral and myocardial biomarkers and reduce the length of intensive care unit stays (Li et al., 2011). Although clinical trials for HBOT have not been deemed overwhelmingly successful, the potential clinical significance of HBOT cannot be ignored, and further trials to elucidate the best methods should be pursued (Hu et al., 2016). With an increasing number of clinical trials being conducted, cerebral plasticity has been identified as a benefit of HBOT; however, these trials lack the necessary results to unequivocally conclude efficacy (Zhai et al., 2016). In a recent clinical study, the efficacy of HBOT in restoring memory function for chronic stroke patients was examined, revealing significant memory improvement following HBOT treatment, which was accompanied by an increased brain metabolic rate (Ploughman et al., 2015). Another clinical study utilized HBOT 5 days per week for patients with chronic stroke, and resulted in significant improvements in memory and attention testing scores (Hadanny et al., 2015). The timing of HBOT application has been examined through several clinical studies. Consistent with the preclinical studies discussed above, these studies found that the earlier HBOT is initiated in relation to the initial ischemic event, the greater its therapeutic effectiveness (Chang et al., 2000; Ding et al., 2014). Once past 12 hours post-ischemia, the benefits of single treatment HBOT are drastically reduced, although the application of repetitive HBOT use in the sub-

acute stroke brain has documented neurogenic effects (Hu et al., 2014). Apparent from the completed clinical trials of HBOT for stroke is the consistent safety of this therapeutic strategy, despite inconsistent efficacy. These studies elucidate the clinical potential of using HBOT for chronic stroke patients, but the data are far more varied in acute stroke patients.

3.0 Unpacking the Mechanisms of Action of HBOT in Stroke

3.1 Physiological and metabolic effects

Neurons are particularly susceptible to oxygen deprivation, and thus the primary mechanism of acute HBOT delivery is to increase perfusion and oxygenation of at-risk tissue. Studies have consistently demonstrated that HBOT therapy can enhance arterial oxygen saturation and increase tissue oxygen content through enhanced cerebral microcirculation (Matchett et al., 2009; Zhai et al., 2016). Moreover, HBOT enhances BBB stability through various molecular mechanisms including MMP regulation (Ding et al., 2014), decreases intracranial pressure, and relieves cerebral edema (Zhai et al., 2016). Secondary effects of HBOT in the stroke brain may result from metabolic regulation such as reducing extracellular glutamate levels, which contribute to excitotoxic death and neural dysfunction (Gao-Yu et al., 2011).

3.2 Antioxidant effects

As will be discussed later, introducing high O₂ levels can actually induce oxidative stress; however, in an apparent paradox, HBOT has been consistently shown to confer oxidative protection against stroke-induced ROS and nitrosative species (Li et al., 2008). HBOT treatment following stroke has been shown to reduce the levels of pro-oxidative enzymes such as malondialdehyde and to increase the antioxidant activity of CAT and SOD (Li et al., 2008). Other studies have found reduced stroke-generated ROS, such as hydroxyl free radicals in the striatum following HBOT therapy (Yang et al., 2010). Complex effects of HBOT on nitric oxide synthase have also been implicated in its antioxidant protective properties (Zhou et al., 2012). The counterintuitive effects of HBOT on reducing oxidative damage may result both from our incomplete understanding of HBOT mechanisms and from variations in experimental pressure and duration of treatment sessions. Moderate treatment protocols may simultaneously induce a degree of oxidative stress yet compensate for this through other antioxidant mechanisms. Regardless, additional studies into the intricacies of HBOT's effects on oxidative pathways are necessary.

3.3 Anti-inflammatory effects

Runaway inflammation is recognized as a cornerstone of stroke secondary cell-death pathology, and its sequestration is known to improve functional outcomes (Borlongan et al., 2012). General markers of inflammation, such as tumor necrosis factor alpha, have been observed to decrease in HBOT-treated animals following stroke (Yu et al., 2015), while specific subpopulations of immune cells, such as CD40+ microglia, have also been demonstrated to decline following HBOT (Lavrnja et al., 2015). Inhibition of leukocyte accumulation within the ischemic area was found in HBOT-treated animals and was attributed to a reduction in the levels of inflammatory chemokines (Rink et al., 2010). Similarly, a study found that HBOT reduced myeloperoxidase activity – an indirect measure of inflammatory response – and inhibited neutrophil infiltration (Miljkovic-Lolic et al.,

2003). The COX-2 signaling pathway has been proposed as a possible underlying mechanism of the HBOT-mediated reduction in inflammation (Cheng et al., 2011).

3.4 Additional neuroprotective mechanisms

A plethora of molecular pathways have been shown to be modulated by HBOT, which contribute to reduction in apoptosis and preservation of neural tissue. Many of these are intimately connected with the mechanisms described in this section, as neuronal apoptosis is an endpoint outcome commonly resulting from ROS, metabolic restriction, and inflammatory response; however, discrete pathways may also contribute to the protective effects of HBOT. Among those reported are a reduction in HIF-1 α (Sun et al., 2008), decreased cortical and hippocampal caspase-3 (Calvert et al., 2003), increased growth factors such as GDNF and NGF (Zhang et al., 2012), and mitochondrial regulation (Lou et al., 2006). Finally, direct effects on glial cells have been suggested to assist in preserving susceptible neurons (Gunther et al., 2005).

4.0 Implications of HBOT in Other Neurological and Non-neurological Conditions

4.1 HBOT in acute and chronic TBI

A large number of studies have demonstrated the safety and effectiveness of HBOT in diverse models of traumatic brain injury (TBI), especially within the acute phase (Zhang et al., 2012; Lim et al., 2013; Wee et al., 2015; Lim et al., 2017). One such study evaluated HBOT (2.8 ATA, 45 min, twice a day for three consecutive days) initiated 3 hours after a dynamic cortical deformation model of TBI, and revealed significant histopathological alterations indicating HBOT effectiveness (Vlodavsky et al., 2006). In another study, mice with moderate closed head weight drop traumatic brain injury (mTBI) treated with HBOT (2 ATA, 60 min, four consecutive days) initiated at either 3 hours or 7 days post-injury exhibited significant recovery of learning and cognitive abilities compared to non-treated controls, displaying performance comparable to sham mice (Baratz-Goldstein et al., 2017). Despite wide-ranging variations in pre-clinical and clinical HBOT protocol, a meta-analysis of its clinical application in acute TBI revealed legitimate and consistent effectiveness in conferring neuroprotection (Wang et al., 2016). Clinical evaluations have revealed the potential of HBOT to confer neurorestorative effects in the chronic TBI brain as well; a recent study which initiated HBOT at 6 months to 27 years post-injury in human patients found upregulated angiogenesis and cerebral perfusion associated with improvement in memory, executive functions, information processing speed, and global cognitive scores as measured by an objective computerized exam (Tal et al., 2017). Additional studies of delayed HBOT for chronic TBI have supported these findings (Harch et al., 2012; Boussi-Gross et al., 2013; Tal et al., 2015; Harch et al., 2017), while other studies have provided discrepant results, such as HBOT (1.5 ATA, 90 min) given 60 days post-TBI for 15 consecutive days resulting in no beneficial effects (Yang et al., 2014).

4.2 HBOT in spinal cord injury

Several studies have demonstrated that spinal cord injuries (SCIs) are exacerbated more by secondary injury response mechanisms than by the primary insult (Geng et al., 2015). Secondary cell death mechanisms initiate a cascade of biomolecular events inducing reactive oxidative damage, astrocytic glial scarring, and infiltration of glia, lymphocytes, activated monocytes, and phagocytic macrophages, which may be amenable to HBOT (Oyinbo, 2011). Interestingly, HBOT experimental studies have shown positive therapeutic effects in SCI by providing a neuroprotective microenvironment that decreases anoxic conditions and enhances neuronal regeneration (Wang et al., 2014). For example, a recent report found significant positive alterations in oxidative pathway enzymes, apoptotic markers, and inflammatory mediators (Shams et al., 2017). Other studies have found preservation of BBB integrity following SCI and reversal of motor deficits (Sun et al., 2017). Patients with SCI treated with HBOT exhibited significant improvement of neurological function compared to control group patients, as well as preservation of various neuron physiological functions, such as evoked potential amplitude and conduction velocity (Tan et al., 2018). Postulated mechanisms of action of HBOT in SCI mirror those to be discussed later, but include increased expression of vascular endothelial growth factor (VEGF), axonal regeneration, and decreased apoptosis (Fu et al., 2017).

4.3 HBOT in other pathological contexts

Various disease pathologies that involve molecular cascades accompanied by oxidative stress, inflammation, and ischemia have found therapeutic effects from HBOT (Daruwalla et al., 2006; McDonagh et al., 2007; Danesh-Sani et al., 2012; Borab et al., 2017). Patients with maladies involving tissue hypoxia, including diabetic ulcers, have been examined as HBOT candidates (Londahl, 2012; Londahl, 2013), and acute coronary syndrome benefits from HBOT (Shuvy et al., 2013; Bennett et al., 2015). In addition, disease-specific mechanisms can underlie HBOT effectiveness, such as the antimicrobial properties of HBOT for necrotizing soft tissue infections (Bhutani et al., 2012) or increased gas-dissolution for air embolisms (Perez et al., 2017). Psychological symptoms, such as post-traumatic stress disorder (PTSD) and post-concussive syndrome, which may develop secondary to brain injury, have also displayed favorable responses to HBOT (Boussi-Gross et al., 2013). One study found a reduction in PTSD symptoms following 40 sessions of HBOT (1.5 ATA, 60 min) over the course of 30 days (Harch et al., 2009; Harch et al., 2012). Treated subjects experienced improvements in cognitive function, decreased anxiety/depression, and improved cerebral vascular blood flow in the white matter region (Harch et al., 2017). Finally, spontaneous physiological abnormalities including autism spectrum disorders have been reported as amenable to HBOT (Rossignol et al., 2006), although the evidence for these claims is controversial (Xiong et al., 2016). In summary, apparent from the extensive research into HBOT for non-stroke disorders is its consistent safety profile when delivered within normal protocols for appropriate disease indications.

5.0 Pre-clinical Findings with HBOT Preconditioning for Stroke

A growing body of evidence indicates the therapeutic potential of HBOT delivered prior to ischemic onset (Hu et al., 2016). The introduction of hyperoxia to a healthy brain induces

mild oxidative stress, enabling endogenous cells to develop a greater tolerance to a future insult. Concerns regarding the efficacy of HBOT following stroke have been raised due to oxygen's role in pathways associated with worse outcomes following stroke, such as glutamate-induced excitotoxic cell death (Singhal et al., 2002), as well as general lack of consistent and effective clinical HBOT treatment protocols. However, HBOT preconditioning could circumvent these concerns as mild oxidative stress is not coupled with more significant cerebrovascular events that initiate various apoptotic pathways; rather, HBOT conditions the cells to withstand future cerebrovascular events and their accompanying oxidative damage (Ostrowski et al., 2016). Patient populations at a particularly high risk for stroke (such as those with combinations of key factors such as morbid obesity, hypertension, low physical activity, diabetes mellitus, smoking, history of stroke, etc.) may benefit from preemptive HBOT. Similarly, patients who are diagnosed with carotid artery plaque are considered high-risk patients and could be candidates for preconditioning strategies to minimize damage from potential future strokes (Zhang et al., 2017). Indeed, as the ability of clinicians to accurately predict probable stroke cases advances via imaging techniques, such as magnetic resonance T₂ mapping (Chai et al., 2017), preconditioning therapies, in particular HBOT, will undoubtedly increase in value.

The first published pre-clinical study of HBOT preconditioning in ischemic stroke reported that this strategy conferred ischemic tolerance and prevented neuronal death within the hippocampus of the gerbil brain following forebrain ischemia inflicted 48 hours after the final session (Wada et al., 1996). Subsequent studies showed that HBOT was protective against transient, but not permanent, stroke in a dose-dependent manner, and that a regimen of 5 treatments (2.5 ATA, 1 hour) over consecutive days was more effective than 3 treatments over consecutive days in rescuing functional deficits when initiated 24 hours before transient middle cerebral artery occlusion (MCAO) (Xiong et al., 2000). Independent laboratories have supported these findings, with one study, for example, demonstrating that HBOT (2.5 ATA, 1 hour, twice daily) conferred neurological and histopathological protection from MCAO inflicted 24 hours after the final session (Li et al., 2008). Other investigators have opted for more aggressive treatment protocols – such as 3.5 ATA for 1 hour, five consecutive days – finding significant histopathological signals of neuroprotection following forebrain ischemic stroke inflicted 12 hours after the final HBOT session (Yamashita et al., 2009). The preemptive “therapeutic window” of HBOT has also been explored, with HBOT delivered 24 hours before injury bestowing neuroprotection, but not at 72 hours (Hirata et al., 2007). Importantly, the length of this window may be a function of the intensity and number of HBOT sessions delivered prior to injury.

The mechanisms underlying the effects of HBOT undoubtedly involve several pathways that work in parallel, or independently, to induce preconditioning in the brain (Francis et al., 2017). While the mechanisms of post-injury HBOT were mentioned previously, in the following sections we present a detailed overview of the preclinical studies describing the mechanisms of action proposed to confer therapeutic protection for HBOT delivered before injury onset.

5.1 Preparation for oxidative stress

The chief mechanism of action for HBOT implicated to confer neuroprotection appears to be its action as an oxidative preconditioning agent (Gao et al., 2017). Prolonged hypoxia contributes to oxidative stress, antioxidant system imbalance, and eventual tissue injury. Preconditioning with HBOT can exert a protective role by priming brain tissue for oxidant stress, making it less susceptible to stroke-induced injury mechanisms. It is widely accepted that increased production of ROS and reactive nitrogen species (RNS), such as peroxynitrite or NO₂, makes a major contribution to the development of CNS oxygen toxicity. Cells have evolved several defense strategies against ROS involving antioxidant enzymes, including superoxide dismutase (SOD) to scavenge superoxide, catalases (CAT) and peroxidases to break down hydrogen peroxide, and glutathione S-transferase to neutralize lipid peroxides, as well as their auxiliary enzymes, glutathione reductase (GRX) and glucose-6-phosphate dehydrogenase (G6PD). Low levels of ROS stimulate adaptive responses by increasing the cellular activity of these enzymatic antioxidants, while pathological levels of ROS, such as those produced under conditions of hyperoxia, can overwhelm the antioxidative capacity of the cells and cause oxidative injury. This oxidative stress manifests as protein oxidation, DNA damage with increased mutational rates, and lipid peroxidation, resulting in membrane damage, metabolic perturbation and death (Pisoschi et al., 2015). HBOT produces an elevated O₂ partial pressure and increased mitochondrial generation of H₂O₂, elevating ROS production (Hu et al., 2016). However, several lines of investigation have shown that HBOT induces an initial oxidative stress that acts as a trigger mechanism prompting anti-oxidative responses (Gao et al., 2017).

In a model of focal cerebral ischemia, HBOT preconditioning induced an increase in the activity of SOD and CAT in the brain tissue associated with decreased mortality rate, improved neurological recovery, and lessened neuronal injury (Li et al., 2008). In addition, malondialdehyde (MDA) content, a marker of lipid peroxidation and oxidative stress, decreased in the ischemic penumbra and hippocampus (Li et al., 2008). Since HBOT preconditioning stimulates ROS production, one possible explanation is that modest levels of ROS stimulate compensatory increases of CAT and SOD, which scavenge excessive ROS and attenuate the lipid peroxidation following stroke (Li et al., 2008). Moreover, in a spinal cord ischemia animal model, HBOT preconditioning similarly increased CAT and SOD activities, with the administration of a CAT inhibitor (3-amino-1,2,4-triazole) before ischemia, attenuating the spinal cord ischemic tolerance induced by HBOT preconditioning (Nie et al., 2006). In addition, administration of a free radical scavenger, dimethylthiourea, before preconditioning reversed the increased activities of both enzymes in spinal cord tissue (Nie et al., 2006). The results indicate that an initial oxidative stress upregulates the antioxidant enzyme activities, playing an important role in the formation of the tolerance against ischemic injury by HBOT preconditioning.

Repeated exposure to non-convulsive HBOT provides protection against central nervous system (CNS) oxygen toxicity by decreasing levels of GRX and G6PD, and conferring a significant increase in glutathione peroxidase (GSH-Px) activity, as well as by increasing glutathione S-transferase (GST) activity (Arieli et al., 2014). G6PD catalyzes the oxidation of glucose to generate NADPH from NADP⁺ while NADPH-oxidase catalyzes the

production of superoxide by oxidation of NADPH (Arieli et al., 2014). Hence, by downregulating G6PD activity, HBOT may indirectly reduce oxidative stress. In addition, the decrease of G6PD activity is associated with a downregulation in the activity of GRX and an increase in GSH-Px, indicating that HBOT may upregulate antioxidants and downregulate pro-oxidant enzymes.

In the healthy brain, HBOT induces an increase of heat shock proteins (HSPs), which play important roles in cellular repair and protective mechanisms. HBOT preconditioning has been shown to upregulate HSP70 specifically (Ni et al., 2013), which exerts protective effects including prevention of protein aggregation, refolding of partially denatured proteins, reduction of inflammatory responses, and inhibition of apoptosis (Brown, 2007). Moreover, *in vitro* studies have shown that HBOT preconditioning protects neurons against oxidative injury and oxygen-glucose deprivation (OGD) by upregulating HSP32 expression (Li et al., 2008; Huang et al., 2014). HSP32, also named heme oxygenase-1, degrades heme into three products: carbon monoxide (CO), ferrous iron, and biliverdin. Free heme is produced mainly through the oxidation of hemoproteins, including hemoglobin, myoglobin, and neuroglobin. In the center of heme is a Fe atom that can react with H₂O₂ and gives rise to toxic hydroxyl radicals. Catalysis of heme by HSP32 produces ferritin release, and its accumulation provokes iron sequestration and thus may provide protection against oxidative damage (Li et al., 2008; Huang et al., 2014). In addition, ROS and NO are two well-established inducers of HSP32; of note, HBOT-induced HSP32 expression is mediated via the ROS/p38 MAPK/Nrf2 pathway and by MEK1/2/Bach1-mediated negative regulation (Huang et al., 2016). Oxidative stress resulting in free radical generation should encourage HSP expression, as these studies confirm. However, a study showed no induction of HSP72 expression within peripheral blood mononuclear cells (PBMC) following a single HBOT exposure in healthy males, indicating the importance of cell-specific response to HBOT (Vince et al., 2010).

Another protective effect of HBOT preconditioning against oxidative stress may involve expression of many Nrf2-regulated antioxidant genes. The Nrf2 signaling pathway has the potential to activate over 200 antioxidant and cytoprotective genes (Srivastava et al., 2013). HBOT preconditioning was shown to increase the levels of Nrf2 and enhance some of its target genes such as key proteins for intracellular GSH synthesis and transit (GST, GCL, cGT and MRP1), molecular chaperones (HSP32 and HSPA1A), and anti-oxidative enzymes (SOD1, GST) (Xu et al., 2014; Huang et al., 2016; Perdrizet, 2016; Xue et al., 2016; Zhai et al., 2016). The neuroprotective mechanism of HBOT preconditioning is also mediated by upregulating SirT1 expression in at least three different ways: (1) upstream regulation for fasting-induced activation of the Nrf2 pathway by affecting the activity of the PPAR- γ /PGC1-1 α complex that binds to Nrf2 promoter and activates its expression; (2) inhibition of apoptosis by increasing the protein expression of anti-apoptotic Bcl-2, decreased pro-apoptotic cleaved caspase-3, deacetylating p53; (3) upregulation of FoxO, promoting the expression of SOD and CAT in response to oxidative stress (Zeng et al., 2012; Yan et al., 2013; Bian et al., 2015; Xue et al., 2016; Ding et al., 2017).

Exposure to HBOT is associated with increased levels of nitric oxide (NO) (Goldstein et al., 2006; Liu et al., 2008; Arieli et al., 2014). NO acts as an important neurotransmitter and plays a dual role in both neuroprotection and neurotoxicity depending on the NO synthase

(NOS) isoform, the cell type by which it is produced, as well as the temporal stage after ischemic onset (Chen et al., 2017). Immediately after brain ischemia, NO release from endothelial NOS (eNOS) is protective mainly by promoting vasodilation; however, after ischemia develops, NO produced by overactivation of neuronal NOS (nNOS) and expression of iNOS both contribute to brain damage. While nNOS-derived NO decreases neurogenesis, NO produced by eNOS and iNOS seems to stimulate it (Sawada et al., 2009). NO, as a vasodilator of cerebral vessels, can increase tissue oxygenation, yet may also increase the delivery of ROS to tissue. In addition, NO can combine with oxygen radicals to form the potent oxidant peroxynitrite and induce nitrosative stress. However, it was shown that HBOT preconditioning has a protective effect involving alterations in the enzymatic activity of the antioxidant system and lower levels of peroxynitrite mainly in the hippocampus (Arieli et al., 2014).

The increase of eNOS and nNOS mRNA/proteins in hypothalamus and hippocampus, as well as the elevated NO, may enhance the sensitivity to convulsions after repeated HBOT exposures, potentially leading to seizures during the subsequent oxygen exposures (Liu et al., 2008). Interestingly, the increase of Mn-SOD, CAT and Bcl-2 and the reduction of apoptosis seem to be mediated by NO, because the neuroprotective effect of HBOT preconditioning is abolished by a nonspecific NOS inhibitor, L-NAME (Wang et al., 2009). These results suggest that NO after HBOT preconditioning exerts both neuroprotection and neurotoxicity, indicating that further studies are needed to better understand the role of NO in HBOT preconditioning.

5.2 Reduction of apoptosis, activation of autophagy, and promotion of cell survival

ROS can react with macromolecular components and induce the cells to undergo necrosis or apoptosis. Inhibition of thioredoxin reductases (TrxR), one of the major redox systems in cells involved in the control of cellular redox balance, has been shown to result in generation of ROS and induced cell apoptosis in neuronal cell lines (Seyfried et al., 2007). In a post-traumatic stress disorder (PTSD)-induced rat model, HBOT preconditioning upregulated the expression of TrxR-1 and TrxR-2 mRNA in the hippocampus concurrent with a reduction in neuronal apoptosis and preserved viable neurons (Peng et al., 2010). Further evidence demonstrated that HBOT preconditioning lessens apoptosis via mitochondrial pathway modulation. In particular, a decrease in the activity of capase-3 and -9, and reduced cytoplasm cytochrome c levels were shown to upregulate the ratio of Bcl-2 and Bax proteins associated with reduced brain edema, decreased infarction volume, and improved neurological recovery (Li et al., 2008; Li et al., 2009; Wang et al., 2010; Lu et al., 2012; Lu et al., 2013). Moreover, the reduction in apoptosis was associated with Mn-SOD and CAT increase and elevated NO after HBOT preconditioning (Wang et al., 2009). Additionally, HBOT preconditioning reduces early apoptosis and apoptosis progression through induction of BDNF and suppression of p38/MAPK phosphorylation (Ostrowski et al., 2008; Yamashita et al., 2009). As mentioned above, HBOT preconditioning can limit apoptosis through the upregulation of SirT1 expression, which increases expression of anti-apoptotic Bcl-2, decreases pro-apoptotic cleaved caspase-3, and deacetylates p53 (Yan et al., 2013).

Interestingly, ROS also regulate starvation-induced autophagy, which is clearly a survival mechanism, partly through the class III phosphoinositide 3-kinase pathway (Wang et al., 2010). It was shown that HBOT preconditioning significantly increases the level of protein expression of LC3-II and Beclin 1 and induces autophagosome formation in the ischemic penumbra following ischemia in rat brain (Yan et al., 2011). Therefore, autophagy can be activated by ROS and may confer neuroprotection. Another mechanism by which HBOT preconditioning can promote cell survival is by reducing matrix MMP-9 activity/tissue expression, which plays a deleterious role after global cerebral ischemia. HBOT preconditioning suppressed post-ischemic MMP-9 activity, CA1 cell damage, and improved functional performance (Ostrowski et al., 2010).

Finally, HBOT preconditioning can promote proliferation and counter cell loss through different mechanisms including activation of the Wnt signaling pathway, secretion of vascular endothelial growth factor (VEGF) and upregulation of HIF-1 (Wang et al., 2007). It was shown that the levels of VEGF, VEGFR2, Raf-1, MEK1/2, and phospho-extracellular signal-regulated kinase (ERK) 1/2 protein were boosted by HBOT, which was associated with NSC proliferation and migration to the lesion area, and improved neurological function (Yang et al., 2017).

5.3 Immunosuppression and immunopreparation

Reducing and preventing aberrant inflammation is another prominent mechanism of HBOT preconditioning (Hu et al., 2016). HBOT preconditioning was shown to reduce the expression of neurotoxicity microglia alongside a decrease in TNF- α and neuronal degeneration, all of which is connected with reduced cerebral edema and amelioration of motor dysfunction after intracerebral hemorrhage (Yang et al., 2015). Moreover, HBOT preconditioning reduced cyclooxygenase-2 (COX-2) expression (which is involved in post-ischemic neuroinflammation), increased the level of surviving neurons in the CA1, attenuated post-operative brain edema, and improved neurological outcomes after global ischemia and surgical brain injury (Jadhav et al., 2009; Cheng et al., 2011). Preconditioning with HBOT also regulates the expression of Osteopontin (OPN), which was shown to reduce the expression of interleukin (IL)-1 β /nuclear factor- κ -gene binding (NF κ B) and to augment protein kinase B (Akt) (Hu et al., 2015). HBOT preconditioning could significantly mitigate cognitive impairment and preserve other physiological functions via reduction of systemic and hippocampal pro-inflammatory cytokines and caspase-3 activity (Gomez et al., 2012; Sun et al., 2014).

5.4 Preservation of blood-brain barrier, edema minimization, and angiogenesis

HBOT preconditioning has been shown to attenuate brain edema and improve neurological outcomes following surgical brain injury (SBI), ischemic and hemorrhagic stroke, TBI and high altitude exposure (Qin et al., 2007; Hu et al., 2008; Jadhav et al., 2010; Lin et al., 2012; Soejima et al., 2012; Soejima et al., 2013; Fang et al., 2015; Hu et al., 2015; Guo et al., 2016). HBOT preconditioning may reduce edema and protect the BBB by suppressing the inflammatory response. It was shown that HBOT preconditioning decreased both infarction and hemorrhage volumes, and improved neurobehavioral function through reduced expression of the NLRP3 inflammasome and its downstream targets after hemorrhagic

transformation (Guo et al., 2016). Moreover, HBOT preconditioning reduces cerebral vasospasm and stabilizes the blood–brain barrier (BBB) by increasing OPN expression in the brain, inhibiting IL-1 β /NF κ B, and suppressing MMP-9 (Hu et al., 2015). In support of this, some studies showed that HBOT preconditioning improved neurological deficits and reduced hemorrhagic volume via decreasing HIF-1 α and its downstream MMP-2 and MMP-9 (Hu et al., 2008; Ostrowski et al., 2008; Soejima et al., 2013). In addition, it was shown that HBOT preconditioning may depend on the induction of MMP-9 in the pre-ischemic phase and may be in part mediated by exhaustion of MMP-9 stores in cerebral tissues (Ostrowski et al., 2008).

HBOT preconditioning-induced HSP-70 overexpression in the hippocampus can significantly attenuate brain edema, cognitive deficits, and hippocampal oxidative stress (Lin et al., 2012). It was indicated that HBOT preconditioning can induce cytoprotective effects on human microvascular endothelial cells via upregulation of Nrf2 and HSP32 or heme oxygenase-1 (Godman et al., 2010). However, more recently it was shown that HBOT improved neurological deficits, infarction volume, BBB disruption, and hemorrhagic transformation without including the activation of these proteins in a focal cerebral ischemia model (Soejima et al., 2012).

Reduced intracerebral edema may also be achieved with HBOT preconditioning by downregulating the expression of aquaporin 4 (AQP-4), a key factor that effects the water and electrolyte balance in the CNS, thus impeding intracerebral hemorrhage and protecting neural tissue (Fang et al., 2015). On the other hand, it was shown that levels of both AQP-4 and VEGF were significantly increased in cultured astrocytes after HBOT preconditioning (Wang et al., 2016). These findings suggest that HBOT preconditioning is also able to promote transient and regulated BBB opening, which may contribute to the induction of cerebral ischemic tolerance as well as representing a possible strategy for promoting drug transport into the CNS (Wang et al., 2016). In addition, it was shown that preconditioning with HBOT protects against brain edema formation following intracerebral hemorrhage by activation of the p44/42 MAPK pathway, whose activation has been linked to ischemic tolerance (Qin et al., 2007). Changes in tight junction protein (TJP) expression can lead to the loss of BBB integrity and BBB breakdown. Interestingly, it was shown that HBOT preconditioning protected the integrity of the BBB in an *in vitro* model through modulation of occludin and ZO-1 expression under hypoxic conditions (Hao et al., 2016).

Finally, HBOT preconditioning may exert protective effects on energy metabolism and tissue perfusion by 1) stabilizing the glucose level; 2) decreasing the lactate/pyruvate ratios and glycerol in the peri-infarct area; 3) inhibiting the increase of the glutamate level; and 4) upregulating Ang-2, which is associated with increased microvessel density in the penumbra, reduced brain injury, and improved neurological function after focal cerebral ischemia (Gao-Yu et al., 2011; Duan et al., 2015).

5.5 Considerations for HBOT preconditioning protocols

The constituent components of HBOT (hyperoxia and hyperbaricity) are critical for the induction of tolerance against ischemic injury since simple hyperbaricity (2.5 ATA, 21% O₂) did not induce ischemic tolerance (Dong et al., 2002). Interestingly, there is a close link

between hyperoxia and hypoxia (Mik, 2011). HBOT and hypoxic preconditioning elicit similar preconditioning efficacy in neonatal brain, but invoke different defenses against oxidative stress (Freiberger et al., 2006). Usually, the HBOT preconditioning is carried out at 2–3 ATA and the duration of each exposure ranges from 60 to 90 minutes (Theodoraki et al., 2011; Liu et al., 2012; Losada et al., 2014). The interval of 24 hours is the most commonly applied in HBOT preconditioning (Theodoraki et al., 2011; Liu et al., 2012). Serial exposition for 3 or 5 days at HBOT preconditioning can induce ischemic tolerance in a dose-dependent manner (Xiong et al., 2000; Dong et al., 2002). Interestingly, HBOT-induced neuroprotection against ischemic injury appears to have a time window, showing protection at 6 h, 12 h and 24 h pre-stroke, but not at 72 h (Hirata, 2007). However, neuroprotection induced by preconditioning consists of biphasic time windows defined by immediate and delayed preconditioning effects (Yokobori et al., 2013; Hu et al., 2016). Immediate preconditioning is observed within 1 h after the preconditioning stimulus and is characterized by transient changes in activity of ion channels, secondary messengers, and enzyme activity (Yokobori et al., 2013). Delayed preconditioning consists of intracellular changes that develop more slowly and manifest as long-lasting alterations in gene expression and protein expression profiles (Yokobori et al., 2013).

6.0 HBOT-primed Stem Cells as a Promising Therapy

Present within discrete niches of the adult brain, stem cells exert neuroprotective and neurorestorative effects following stroke by migrating to infarcted and damaged regions whereby they utilize multi-pronged therapeutic tactics to confer their benefits (Sullivan et al., 2015). Among the mechanisms employed by these undifferentiated cells are bystander effects, such as secretion of trophic factors, anti-inflammatory molecules, apoptotic pathway regulators, and angiogenic factors (Napoli et al., 2018) and, to a much lesser extent, direct cell replacement of damaged neural tissue (Stonesifer et al., 2017). Unfortunately, the ability of unaided endogenous stem cells to initiate robust recovery following stroke is extremely limited. In this light, therapeutic modalities that enhance the brain's intrinsic reparative capacity are highly attractive. A growing body of literature supports enhancing the effects of HBOT on endogenous stem cells as a prominent mechanism of action in the post-stroke brain (Thom et al., 2006). This knowledge – in addition to supporting the previously discussed concepts of HBOT as a standalone therapy for stroke or prophylactic treatment – indicates a possible role for HBOT in conditioning of stem cells prior to transplantation. The following sections will discuss the effects of HBOT on stem cells, and how these effects may be lent favorably to a stem cell preconditioning paradigm.

6.1 HBOT effects on endogenous and transplant stem cell populations

HBOT exerts dynamic effects on various populations of stem cells *in vivo*. Perhaps most prominently, HBOT enhances the total number of available endogenous stem cells by increasing the quantity of circulating stem cells in a pressure-sensitive manner (Thom et al., 2006; Dhar et al., 2012; Heyboer et al., 2014) and upregulating neural stem cell proliferation within the neurogenic niches of the adult brain (Yang et al., 2008). This phenomenon has been demonstrated in multiple injury models including heightened sub-ventricular zone (SVZ) and sub-granular zone (SGZ) proliferation following ischemic brain damage (Yang et

al., 2008; Wei et al., 2015), increased neural stem cell proliferation in the piriform cortex in the vascular dementia brain (Zhang et al., 2010), and upregulation of both neural stem cell proliferation (Yang et al., 2017) and circulating stem cells (Shandley et al., 2017) following TBI. Moreover, this effect has been observed in non-oxy-injured animals (Heyboer et al., 2014), insinuating the potential for therapeutic effectiveness independent of pathological idiosyncrasies, as well as for pre-injury applications. In addition to encouraging proliferation of neural stem cells, HBOT promotes their migration to areas of injury, as demonstrated in a rat model of TBI (Yang et al., 2017). Furthermore, of the various stem cells which are released into circulation following HBOT, particular subsets – such as vasogenic endothelial progenitor cells (EPCs) – may enact particularly potent effects in the stroke brain (Thom et al., 2011). Paired with the mechanisms described in Sections 3 and 5, the presence of heightened stem cell numbers in the periphery and brain likely contribute to the therapeutic benefits of HBOT observed in the stroke brain.

Of great interest are the mechanisms by which HBOT increases available stem cells within the body. The circulating stem cells released following HBOT originate from the bone marrow, and their departure into circulation is largely attributed to heightened nitric oxide synthesis by eNOS (Heyboer et al., 2014). Experiments using eNOS-knockout mice and nitric oxide synthase inhibitors support this concept (Thom et al., 2006). The mechanisms underlying HBOT-induced upregulation of cerebral neurogenesis, however, are more elusive and likely multi-factorial. A number of key signaling molecules and growth factors modulated by HBOT have been identified and may be responsible for the increase (Mu et al., 2011). Among these, HBOT is known to exert a stabilizing effect on HIF-1 α , a transcription factor specifically activated by hypoxia, slowing its degradation by the prolyl hydroxylase pathway (Milosevic et al., 2009) and allowing for increased activation of the Wnt/ β -catenin signaling pathway, which has been directly linked to neural stem cell proliferation (Qi et al., 2017). Supporting this, Wnt-3 expression was observed to increase substantially in HBOT-treated ischemic-hypoxia neonate rats in parallel with elevated SVZ neurogenesis (Wang et al., 2007). Particularly interesting, studies have reported that high levels of ROS within proliferative NSCs may serve secondary messenger functions which contribute to their self-renewal, and that pharmacological inhibition of ROS reduces their proliferative capacity (La Belle et al., 2011). Thus, an HBOT-induced increase in ROS levels may increase NSC levels by enhancing signaling pathways which are intrinsically linked to NSC survival and proliferation.

HBOT may also promote neural stem cell proliferation via upregulation of key regulatory molecules such as vascular endothelial growth factor (VEGF) (a downstream target of HIF-1 α), its receptor (VEGFR2) (Yang et al., 2017), ERK (Jiang et al., 2015), and CREB (Zhu et al., 2004; Mendoza-Paredes et al., 2008) – all of which play roles in neurogenic pathways (Lu et al., 2011). HIF-1 α induces the expression of hundreds of gene products in response to hypoxia or ischemia involved in processes such as angiogenesis, glycolysis, inflammation, proliferation and growth, which collectively promote cell survival and neuroprotection after brain injury (Milosevic et al., 2009; Hu et al., 2016). It was shown that erythropoietin (EPO), another target gene of HIF-1 α , was upregulated in the cerebral cortex and hippocampus and prevented changes to BBB permeability, decreased brain edema, reduced infarction volumes, and improved neurobehavioral outcome after HBOT (Gu et al.,

2008; Peng et al., 2008). Conversely, it has also been shown that a systemic reduction in EPO levels by HBOT promotes bone marrow homing and engraftment after allogeneic umbilical cord blood (UCB)-derived hematopoietic stem/progenitor cell (HSPC) transplantation (Aljitiawi et al., 2016). In addition, the increased nuclear expression of HIF-1 α following HBOT is associated with increased expression of CXCR4 (Chen et al., 2017). A recent study showed that the HIF-1 α -CXCR4 pathway can promote proliferation of neural crest stem/progenitor cells (NCSCs) by decreasing nuclear expression of the cyclin-dependent kinase inhibitor CDKN1A (p21CIP1/WAF1) and by SDF-1/CXCL12 signaling mediated by receptor CXCR4 under hypoxia (Chen et al., 2017). Moreover, after HBOT, increased cytoplasmic expression of TPM1 and decreased nuclear expression of TP53 and CDKN1A resulted in decreased apoptosis and increased proliferation of NCSCs (Chen et al., 2017). Finally, HBOT-induced vascularization may increase neurogenesis by providing metabolic support to under-perfused neurogenic areas (Tal et al., 2017).

6.2 HBOT and exogenous stem cells

A careful analysis of combining HBOT with stem cell transplantation offers insight into potential underlying mechanisms and interplay between the two treatments. This combinatorial approach has been studied in a number of neurological and non-neurological contexts including TBI (Zhou et al., 2016), SCI (Geng et al., 2015) and diabetes mellitus (Estrada et al., 2008). One study demonstrated that HBOT improves graft survival within the bone marrow, peripheral blood, and spleen following umbilical cord blood stem cell transplantation in a rodent model of whole-body irradiation injury (Aljitiawi et al., 2014). Similar results were found in a model of SCI, with greater MSC graft survival found in HBOT+cell therapy animals than in cell therapy alone (Geng et al., 2015). Animals receiving the combination therapy were also observed to have an assuaged inflammatory response, with lower levels of pro-inflammatory mediators TNF- α , IL-6, and IFN- α at various time points when compared to animals receiving cell therapy alone (Geng et al., 2015). In a traumatic nerve crush model, transplantation of human amniotic fluid mesenchymal stem cell (AFS) delivered with adjunctive HBOT displayed synergistic effects (Pan et al., 2009). Among the improvements reported in this study were a suppressed inflammatory response in combination therapy animals, upregulated nerve regeneration metrics such as neurofilament production and s-100 expression, and, interestingly, a dramatic decrease in expression of the apoptosis marker TUNEL in the transplanted AFS (Pan et al., 2009).

6.3 Effects of HBOT *in vitro*: potential for stem cell priming

In light of the broad effects of HBOT on endogenous and transplanted stem cells, further investigations into the effects of HBOT on stem cells *in vitro* are warranted. Importantly, many of the molecular signaling pathways which are discussed above (i.e. Wnt/ β -catenin, VEGF/VEGFR2, and CREB) are likely mediated by non-stem cell host tissue secretions. Thus, while the knowledge obtained from studies of HBOT on stem cells *in vivo* guides our scientific inquiries, the mechanisms, both stem cell- and non-stem cell-mediated, must be considered. Moreover, potential adverse effects of HBOT on stem cells should also be examined. Indeed, *in vitro* study of HBOT on stem cells has found unique effects on stem cell cultures. In contrast to the paradigm described previously of HBOT-mediated increase in

stem cell proliferation, HBOT was shown to decrease cell survival in mesenchymal stem cell (MSC) cultures (Schulze et al., 2017). The enhanced oxygen tension delivered by HBOT increases the formation of ROS and exerts oxidative stress on cells (Thom, 2009; Cheung et al., 2018). Similar results have been reported with other stem cell populations, including umbilical cord blood stem cells (Cheung et al., 2018).

The therapeutic potential of HBOT priming stem cells for subsequent transplantation will also require careful evaluation, as exposure to oxidative stress *in vitro* may improve stem cell resiliency to oxidative stress upon transplantation (employing a similar conceptual framework as described for HBOT preconditioning in Section 5). With this in consideration, we propose that *in vitro* HBOT priming may have genetic, molecular, or transcriptomic effects on stem cells which increase their therapeutic potential, and further, that preliminary HBOT-induced oxidative stress may improve the resiliency of these stem cells to the harmful microenvironment of the post-stroke brain upon transplantation.

This strategy of HBOT-primed stem cells has been employed in a limited fashion in other pathological contexts; human adipose-derived stem cells were demonstrated to have improved extracellular matrix-secreting capabilities following transplant into a rabbit cartilage defect model when primed with 2.5 ATA HBOT for 1 hour (Dai et al., 2015). In another study, increased O₂ exposure *in vitro* prompted the maturation and differentiation of human embryonic stem cell-derived pancreatic progenitor cells into the desired β -cell lineage (Cechin et al., 2014).

Precedent evidence on priming exists for this therapeutic approach in stroke as well. Hypoxic preconditioning of stem cells (5% O₂ for 24 hours) has been shown to increase graft survival post-transplantation in a hemorrhagic stroke mouse model (Wakai et al., 2016) and an ischemic stroke model (23031629), as well as to enhance stem cell migratory/homing ability (Hu et al., 2011; Lee et al., 2013; Wei et al., 2013). By preparing stem cells for the metabolic challenges posed by the microenvironment of damaged tissue, post-transplantation cell survival and function are bolstered (Wei et al., 2012). Hypoxia is a major contributor to low graft survival following post-stroke transplantation and serves as the premise for hypoxic preconditioning, yet it is not the only prevalent challenge posed to cells within the post-stroke brain. Rampant oxidative stress contributes significantly to both endogenous cell and graft cell death (Chen et al., 2011; Xing et al., 2012). As such, exposing stem cells to mild/moderate oxidative stress before transplantation may extend their survival time in a similar manner to hypoxic preconditioning by permitting their genetic and phenotypic acclimation to a state of oxidative stress.

HBOT may also alter and enhance the stem cell secretome, boosting its effectiveness within the stroke brain. *In vitro* experiments have revealed that HBOT exerts a notable effect on the secretion profile of stem cells, including a number of proteins implicated in: 1) the oxidative stress response such as vascorin, thrombospondin-4, thioredoxin, heat shock protein (HSP) 90, HSP70, and gamma-glutamylcyclotransferase; and 2) various neuroprotective pathways such as peroxiredoxin, cystatin C, laminin, syndecan and thymosin-beta (Schulze et al., 2017). The increased cellular nitric oxide recorded following HBOT consequently upregulates expression of certain growth factors including VEGF and transforming growth

factor-beta 1 (TFG β 1) (Venetsanou et al., 2012). Moreover, using MSC cultures, HBOT was shown to increase expression of placental growth factor (PIGF) in a dose-dependent manner, which was associated with increased MSC tubule formation and enhanced migratory ability (Shyu et al., 2008). Interestingly, HBOT has been shown to prevent differentiation of stem cells in culture (Cheung et al., 2018). Depending on the treatment strategy of transplantation (i.e. direct cell replacement paradigms such as with oligodendrocyte progenitor cell transplantation, or immunomodulation paradigms such as with MSC transplantation), the ability to promote or maintain naïve stem cell states may be an additional benefit of HBOT priming.

Interestingly, HBOT-preconditioned stem cells may be an effective adjunctive to HBOT-preconditioning of the host. Given the extensive evidence supporting the neuroprotective capacity of HBOT-preconditioning on the healthy brain (see Section 5), stem cell preconditioning could also be executed in tandem to offer a readily available cell therapy option following stroke. This could present a potent dual therapy approach for patients at an exceptionally high risk for stroke, utilizing both a preemptive neuroprotective modality as well as a post hoc neurorestorative biologic.

In summary, the ability of HBOT to prolong graft survival via oxidative stress conditioning, prevent premature differentiation, enhance migratory capacity, promote injury homing, upregulate trophic factors within the secretome, and encourage anti-inflammatory mediation all indicate the great potential of HBOT to advance the therapeutic efficacy of stem cells transplanted in the stroke brain alone, or in synchrony with host preconditioning therapies.

7.0 Future Directions and Conclusion

Preclinical studies have demonstrated the efficacy of HBOT in preserving vulnerable neural tissue and improving functional outcomes in various stroke models. A wide range of HBOT regimens have been reported as effective, with 1) pressures ranging from 2.0 ATA-3.0ATA, 2) durations lasting from 45 min-2 hrs, and 3) time of initiation ranging from immediately after stroke to 48+ hours. Unfortunately, the wide range of effective parameters has prevented a consensus regimen from being employed in clinical trials, slowing the progress of HBOT translation. Compounding this issue, human effectiveness has not been well proven due to a lack of high-quality multicenter randomized controlled trials. The successful translation of clinical HBOT will largely rest on the field's ability to organize and implement standardization and rigorous methodology in its clinical trials. Nonetheless, the basic science field has continued to advance our understanding of the mechanisms of HBOT in the injured and healthy brain, and this has paved the way for the emergence of HBOT preconditioning paradigms. While preconditioning strategies are innovative and may hold real benefits for certain patient populations, obvious limitations exist regarding the ability to preemptively deliver stroke therapy; strokes are acute events which are unpredictable even in patients with extensive predispositions.

In light of these challenges – namely, the difficulties in translating canonical HBOT therapy, and limited application of preconditioning – we propose here a novel application of HBOT as a preconditioning mechanism for stem cell transplantations (Figure 1). Based on the

extensive literature, we speculate that oxidative preconditioning of stem cell grafts via HBOT may be an effective means of increasing graft survival and optimizing graft function within the post-ischemic environment. Advancing this concept will require due diligence in verifying the genetic, epigenetic, secretome, and functional influence that HBOT exerts on specific stem cell populations, and characterizing the *in vivo* response of HBOT-primed versus non-primed stem cells. This therapeutic strategy may be able to harness the promising laboratory findings that have been widely reported for both HBOT and stem cell transplantation following cerebrovascular accident, offering a hybrid approach of either standalone or combinatorial pre-conditioning strategies for conferring neuroprotection in the stroke brain.

Acknowledgments

CVB is funded by NIH R01NS071956, NIH R01 NS090962, NIH R21NS089851, NIH R21 NS094087, and VA Merit Review I01 BX001407.

References

- Aljritawi OS, Paul S, Ganguly A, Lin TL, Ganguly S, Vielhauer G, Capitano ML, Cantilena A, Lipe B, Mahnken JD, Wise A, Berry A, Singh AK, Shune L, Lominska C, Abhyankar S, Allin D, Laughlin M, McGuirk JP, Broxmeyer HE. Erythropoietin modulation is associated with improved homing and engraftment after umbilical cord blood transplantation. *Blood*. 2016; 128(25):3000–3010. [PubMed: 27760758]
- Aljritawi OS, Xiao Y, Eskew JD, Parelkar NK, Swink M, Radel J, Lin TL, Kimler BF, Mahnken JD, McGuirk JP, Broxmeyer HE, Vielhauer G. Hyperbaric oxygen improves engraftment of ex-vivo expanded and gene transduced human CD34(+) cells in a murine model of umbilical cord blood transplantation. *Blood Cells Mol Dis*. 2014; 52(1):59–67. [PubMed: 23953010]
- Arieli Y, Kotler D, Eynan M, Hochman A. Hyperbaric oxygen preconditioning protects rats against CNS oxygen toxicity. *Respir Physiol Neurobiol*. 2014; 197:29–35. [PubMed: 24675062]
- Baratz-Goldstein R, Toussia-Cohen S, Elpaz A, Rubovitch V, Pick CG. Immediate and delayed hyperbaric oxygen therapy as a neuroprotective treatment for traumatic brain injury in mice. *Mol Cell Neurosci*. 2017; 83:74–82. [PubMed: 28690173]
- Bennett MH, Lehm JP, Jepson N. Hyperbaric oxygen therapy for acute coronary syndrome. *Cochrane Database Syst Rev*. 2015; (7):CD004818. [PubMed: 26202854]
- Bennett MH, Weibel S, Wasiake J, Schnabel A, French C, Kranke P. Hyperbaric oxygen therapy for acute ischaemic stroke. *Cochrane Database Syst Rev*. 2014; (11):CD004954. [PubMed: 25387992]
- Bhutani S, Vishwanath G. Hyperbaric oxygen and wound healing. *Indian J Plast Surg*. 2012; 45(2): 316–324. [PubMed: 23162231]
- Bian H, Hu Q, Liang X, Chen D, Li B, Tang J, Zhang JH. Hyperbaric oxygen preconditioning attenuates hemorrhagic transformation through increasing PPARgamma in hyperglycemic MCAO rats. *Exp Neurol*. 2015; 265:22–29. [PubMed: 25542160]
- Borab Z, Mirmanesh MD, Gantz M, Cusano A, Pu LL. Systematic review of hyperbaric oxygen therapy for the treatment of radiation-induced skin necrosis. *J Plast Reconstr Aesthet Surg*. 2017; 70(4):529–538. [PubMed: 28081957]
- Borlongan CV, Glover LE, Sanberg PR, Hess DC. Permeating the blood brain barrier and abrogating the inflammation in stroke: Implications for stroke therapy. *Curr Pharm Des*. 2012; 18(25):3670–3676. [PubMed: 22574981]
- Boussi-Gross R, Golan H, Fishlev G, Bechor Y, Volkov O, Bergan J, Friedman M, Hoofien D, Shlamkovitch N, Ben-Jacob E, Efrati S. Hyperbaric oxygen therapy can improve post concussion syndrome years after mild traumatic brain injury - randomized prospective trial. *PLoS One*. 2013; 8(11):e79995. [PubMed: 24260334]

- Brown IR. Heat shock proteins and protection of the nervous system. *Ann N Y Acad Sci.* 2007; 1113:147–158. [PubMed: 17656567]
- Calvert JW, Zhou C, Nanda A, Zhang JH. Effect of hyperbaric oxygen on apoptosis in neonatal hypoxia-ischemia rat model. *J Appl Physiol* (1985). 2003; 95(5):2072–2080. [PubMed: 14555671]
- Cechin S, Alvarez-Cubela S, Giraldo JA, Molano RD, Villate S, Ricordi C, Pileggi A, Inverardi L, Fraker CA, Dominguez-Bendala J. Influence of in vitro and in vivo oxygen modulation on beta cell differentiation from human embryonic stem cells. *Stem Cells Transl Med.* 2014; 3(3):277–289. [PubMed: 24375542]
- Chai JT, Biasioli L, Li L, Alkhalil M, Galassi F, Darby C, Halliday AW, Hands L, Magee T, Perkins J, Sideso E, Handa A, Jezzard P, Robson MD, Choudhury RP. Quantification of lipid-rich core in carotid atherosclerosis using magnetic resonance T2 mapping: Relation to clinical presentation. *JACC Cardiovasc Imaging.* 2017; 10(7):747–756. [PubMed: 27743954]
- Chang CF, Niu KC, Hoffer BJ, Wang Y, Borlongan CV. Hyperbaric oxygen therapy for treatment of postischemic stroke in adult rats. *Exp Neurol.* 2000; 166(2):298–306. [PubMed: 11085895]
- Chen CC, Hsia CW, Ho CW, Liang CM, Chen CM, Huang KL, Kang BH, Chen YH. Hypoxia and hyperoxia differentially control proliferation of rat neural crest stem cells via distinct regulatory pathways of the HIF1alpha-CXCR4 and TP53-TPM1 proteins. *Dev Dyn.* 2017; 246(3):162–185. [PubMed: 28002632]
- Chen H, Yoshioka H, Kim GS, Jung JE, Okami N, Sakata H, Maier CM, Narasimhan P, Goeders CE, Chan PH. Oxidative stress in ischemic brain damage: Mechanisms of cell death and potential molecular targets for neuroprotection. *Antioxid Redox Signal.* 2011; 14(8):1505–1517. [PubMed: 20812869]
- Cheng O, Ostrowski RP, Wu B, Liu W, Chen C, Zhang JH. Cyclooxygenase-2 mediates hyperbaric oxygen preconditioning in the rat model of transient global cerebral ischemia. *Stroke.* 2011; 42(2):484–490. [PubMed: 21164135]
- Cheung KY, Berry A, Li D, Aljitiwi OS. Hyperbaric oxygen treatment effects on in vitro cultured umbilical cord blood CD34(+) cells. *Cytotherapy.* 2018; 20(1):87–94. [PubMed: 29037940]
- Dai NT, Fan GY, Liou NH, Wang YW, Fu KY, Ma KH, Liu JC, Chang SC, Huang KL, Dai LG, Chen SG, Chen TM. Histochemical and functional improvement of adipose-derived stem cell-based tissue-engineered cartilage by hyperbaric oxygen/air treatment in a rabbit articular defect model. *Ann Plast Surg.* 2015; 74(Suppl 2):S139–145. [PubMed: 25695443]
- Danesh-Sani SA, Shariati-Sarabi Z, Feiz MR. Comprehensive review of hyperbaric oxygen therapy. *J Craniofac Surg.* 2012; 23(5):e483–491. [PubMed: 22976717]
- Daruwalla J, Christophi C. Hyperbaric oxygen therapy for malignancy: A review. *World J Surg.* 2006; 30(12):2112–2131. [PubMed: 17102915]
- Dhar M, Neilsen N, Beatty K, Eaker S, Adair H, Geiser D. Equine peripheral blood-derived mesenchymal stem cells: Isolation, identification, trilineage differentiation and effect of hyperbaric oxygen treatment. *Equine Vet J.* 2012; 44(5):600–605. [PubMed: 22333000]
- Ding P, Ren D, He S, He M, Zhang G, Chen Y, Sang H, Peng Z, Yan W. Sirt1 mediates improvement in cognitive defects induced by focal cerebral ischemia following hyperbaric oxygen preconditioning in rats. *Physiol Res.* 2017; 66(6):1029–1039. [PubMed: 28937253]
- Ding Z, Tong WC, Lu XX, Peng HP. Hyperbaric oxygen therapy in acute ischemic stroke: A review. *Interv Neurol.* 2014; 2(4):201–211. [PubMed: 25337089]
- Dong H, Xiong L, Zhu Z, Chen S, Hou L, Sakabe T. Preconditioning with hyperbaric oxygen and hyperoxia induces tolerance against spinal cord ischemia in rabbits. *Anesthesiology.* 2002; 96(4):907–912. [PubMed: 11964598]
- Duan S, Shao G, Yu L, Ren C. Angiogenesis contributes to the neuroprotection induced by hyperbaric oxygen preconditioning against focal cerebral ischemia in rats. *Int J Neurosci.* 2015; 125(8):625–634. [PubMed: 25171223]
- Estrada EJ, Valacchi F, Nicora E, Brieva S, Esteve C, Echevarria L, Froud T, Bernetti K, Cayetano SM, Velazquez O, Alejandro R, Ricordi C. Combined treatment of intrapancreatic autologous bone marrow stem cells and hyperbaric oxygen in type 2 diabetes mellitus. *Cell Transplant.* 2008; 17(12):1295–1304. [PubMed: 19364067]

- Fang J, Li H, Li G, Wang L. Effect of hyperbaric oxygen preconditioning on peri-hemorrhagic focal edema and aquaporin-4 expression. *Exp Ther Med*. 2015; 10(2):699–704. [PubMed: 26622378]
- Francis A, Baynosa R. Ischaemia-reperfusion injury and hyperbaric oxygen pathways: A review of cellular mechanisms. *Diving Hyperb Med*. 2017; 47(2):110–117. [PubMed: 28641323]
- Freiberger JJ, Suliman HB, Sheng H, McAdoo J, Piantadosi CA, Warner DS. A comparison of hyperbaric oxygen versus hypoxic cerebral preconditioning in neonatal rats. *Brain Res*. 2006; 1075(1):213–222. [PubMed: 16458861]
- Fu H, Li F, Thomas S, Yang Z. Hyperbaric oxygenation alleviates chronic constriction injury (CCI)-induced neuropathic pain and inhibits GABAergic neuron apoptosis in the spinal cord. *Scand J Pain*. 2017; 17:330–338. [PubMed: 28927648]
- Gao-Yu C, Cong-Yina D, Li-Jun Z, Fei L, Hua F. Effects of hyperbaric oxygen preconditioning on energy metabolism and glutamate level in the peri-infarct area following permanent MCAO. *Undersea Hyperb Med*. 2011; 38(2):91–99. [PubMed: 21510268]
- Gao ZX, Rao J, Li YH. Hyperbaric oxygen preconditioning improves postoperative cognitive dysfunction by reducing oxidant stress and inflammation. *Neural Regen Res*. 2017; 12(2):329–336. [PubMed: 28400818]
- Geng CK, Cao HH, Ying X, Yu HL. Effect of mesenchymal stem cells transplantation combining with hyperbaric oxygen therapy on rehabilitation of rat spinal cord injury. *Asian Pac J Trop Med*. 2015; 8(6):468–473. [PubMed: 26194832]
- Geng CK, Cao HH, Ying X, Zhang HT, Yu HL. The effects of hyperbaric oxygen on macrophage polarization after rat spinal cord injury. *Brain Res*. 2015; 1606:68–76. [PubMed: 25724144]
- George MG, Fischer L, Koroshetz W, Bushnell C, Frankel M, Foltz J, Thorpe PG. CDC grand rounds: Public health strategies to prevent and treat strokes. *MMWR Morb Mortal Wkly Rep*. 2017; 66(18):479–481. [PubMed: 28493856]
- Go AS, et al. Executive summary: Heart disease and stroke statistics--2014 update: A report from the American Heart Association. *Circulation*. 2014; 129(3):399–410. [PubMed: 24446411]
- Godman CA, Chheda KP, Hightower LE, Perdrizet G, Shin DG, Giardina C. Hyperbaric oxygen induces a cytoprotective and angiogenic response in human microvascular endothelial cells. *Cell Stress Chaperones*. 2010; 15(4):431–442. [PubMed: 19949909]
- Goldstein LJ, Gallagher KA, Bauer SM, Bauer RJ, Baireddy V, Liu ZJ, Buerk DG, Thom SR, Velazquez OC. Endothelial progenitor cell release into circulation is triggered by hyperoxia-induced increases in bone marrow nitric oxide. *Stem Cells*. 2006; 24(10):2309–2318. [PubMed: 16794267]
- Gomez CR, Knutson GJ, Clifton KB, Schreiber CA, Vuk-Pavlovic S. Age-dependent response of murine female bone marrow cells to hyperbaric oxygen. *Biogerontology*. 2012; 13(3):287–297. [PubMed: 22270336]
- Gu GJ, Li YP, Peng ZY, Xu JJ, Kang ZM, Xu WG, Tao HY, Ostrowski RP, Zhang JH, Sun XJ. Mechanism of ischemic tolerance induced by hyperbaric oxygen preconditioning involves upregulation of hypoxia-inducible factor-1alpha and erythropoietin in rats. *J Appl Physiol* (1985). 2008; 104(4):1185–1191. [PubMed: 18174394]
- Gunther A, Kuppers-Tiedt L, Schneider PM, Kunert I, Berrouschot J, Schneider D, Rossner S. Reduced infarct volume and differential effects on glial cell activation after hyperbaric oxygen treatment in rat permanent focal cerebral ischaemia. *Eur J Neurosci*. 2005; 21(11):3189–3194. [PubMed: 15978027]
- Guo ZN, Xu L, Hu Q, Matei N, Yang P, Tong LS, He Y, Guo Z, Tang J, Yang Y, Zhang JH. Hyperbaric oxygen preconditioning attenuates hemorrhagic transformation through reactive oxygen species/thioredoxin-interacting protein/nod-like receptor protein 3 pathway in hyperglycemic middle cerebral artery occlusion rats. *Crit Care Med*. 2016; 44(6):e403–411. [PubMed: 26646457]
- Hadanny A, Golan H, Fishlev G, Bechor Y, Volkov O, Suzin G, Ben-Jacob E, Efrati S. Hyperbaric oxygen can induce neuroplasticity and improve cognitive functions of patients suffering from anoxic brain damage. *Restor Neurol Neurosci*. 2015; 33(4):471–486. [PubMed: 26409406]
- Hao L, Guo X, Zou C, Zhou H, Tian H, Zhang Y, Song C, Liu L. Hyperbaric oxygen preconditioning ameliorates blood-brain barrier damage induced by hypoxia through modulation of tight junction proteins in an in vitro model. *Croat Med J*. 2016; 57(1):51–57. [PubMed: 26935614]

- Harch PG, Andrews SR, Fogarty EF, Amen D, Pezzullo JC, Lucarini J, Aubrey C, Taylor DV, Staab PK, Van Meter KW. A phase I study of low-pressure hyperbaric oxygen therapy for blast-induced post-concussion syndrome and post-traumatic stress disorder. *J Neurotrauma*. 2012; 29(1):168–185. [PubMed: 22026588]
- Harch PG, Andrews SR, Fogarty EF, Lucarini J, Van Meter KW. Case control study: Hyperbaric oxygen treatment of mild traumatic brain injury persistent post-concussion syndrome and post-traumatic stress disorder. *Med Gas Res*. 2017; 7(3):156–174. [PubMed: 29152209]
- Harch PG, Fogarty EF, Staab PK, Van Meter K. Low pressure hyperbaric oxygen therapy and SPECT brain imaging in the treatment of blast-induced chronic traumatic brain injury (post-concussion syndrome) and post traumatic stress disorder: A case report. *Cases J*. 2009; 2:6538. [PubMed: 19829822]
- Heyboer M 3rd, Milovanova TN, Wojcik S, Grant W, Chin M, Hardy KR, Lambert DS, Logue C, Thom SR. CD34+/CD45-dim stem cell mobilization by hyperbaric oxygen - changes with oxygen dosage. *Stem Cell Res*. 2014; 12(3):638–645. [PubMed: 24642336]
- Hirata T, Cui YJ, Funakoshi T, Mizukami Y, Ishikawa Y, Shibasaki F, Matsumoto M, Sakabe T. The temporal profile of genomic responses and protein synthesis in ischemic tolerance of the rat brain induced by repeated hyperbaric oxygen. *Brain Res*. 2007; 1130(1):214–222. [PubMed: 17173873]
- Hu Q, Liang X, Chen D, Chen Y, Doycheva D, Tang J, Tang J, Zhang JH. Delayed hyperbaric oxygen therapy promotes neurogenesis through reactive oxygen species/hypoxia-inducible factor-1alpha/beta-catenin pathway in middle cerebral artery occlusion rats. *Stroke*. 2014; 45(6):1807–1814. [PubMed: 24757104]
- Hu Q, Manaenko A, Bian H, Guo Z, Huang JL, Guo ZN, Yang P, Tang J, Zhang JH. Hyperbaric oxygen reduces infarction volume and hemorrhagic transformation through ATP/NAD(+)/sirt1 pathway in hyperglycemic middle cerebral artery occlusion rats. *Stroke*. 2017; 48(6):1655–1664. [PubMed: 28495827]
- Hu Q, Manaenko A, Matei N, Guo Z, Xu T, Tang J, Zhang JH. Hyperbaric oxygen preconditioning: A reliable option for neuroprotection. *Med Gas Res*. 2016; 6(1):20–32. [PubMed: 27826420]
- Hu SL, Feng H, Xi GH. Hyperbaric oxygen therapy and preconditioning for ischemic and hemorrhagic stroke. *Med Gas Res*. 2016; 6(4):232–236. [PubMed: 28217297]
- Hu SL, Hu R, Li F, Liu Z, Xia YZ, Cui GY, Feng H. Hyperbaric oxygen preconditioning protects against traumatic brain injury at high altitude. *Acta Neurochir Suppl*. 2008; 105:191–196. [PubMed: 19066108]
- Hu SL, Huang YX, Hu R, Li F, Feng H. Osteopontin mediates hyperbaric oxygen preconditioning-induced neuroprotection against ischemic stroke. *Mol Neurobiol*. 2015; 52(1):236–243. [PubMed: 25146847]
- Hu X, Wei L, Taylor TM, Wei J, Zhou X, Wang JA, Yu SP. Hypoxic preconditioning enhances bone marrow mesenchymal stem cell migration via Kv2.1 channel and FAK activation. *Am J Physiol Cell Physiol*. 2011; 301(2):C362–372. [PubMed: 21562308]
- Huang G, Diao J, Yi H, Xu L, Xu J, Xu W. Signaling pathways involved in HSP32 induction by hyperbaric oxygen in rat spinal neurons. *Redox Biol*. 2016; 10:108–118. [PubMed: 27721085]
- Huang G, Xu J, Xu L, Wang S, Li R, Liu K, Zheng J, Cai Z, Zhang K, Luo Y, Xu W. Hyperbaric oxygen preconditioning induces tolerance against oxidative injury and oxygen-glucose deprivation by up-regulating heat shock protein 32 in rat spinal neurons. *PLoS One*. 2014; 9(1):e85967. [PubMed: 24465817]
- Jadhav V, Ostrowski RP, Tong W, Matus B, Chang C, Zhang JH. Hyperbaric oxygen preconditioning reduces postoperative brain edema and improves neurological outcomes after surgical brain injury. *Acta Neurochir Suppl*. 2010; 106:217–220. [PubMed: 19812952]
- Jadhav V, Ostrowski RP, Tong W, Matus B, Jesunathadas R, Zhang JH. Cyclo-oxygenase-2 mediates hyperbaric oxygen preconditioning-induced neuroprotection in the mouse model of surgical brain injury. *Stroke*. 2009; 40(9):3139–3142. [PubMed: 19628811]
- Jiang P, Zhu T, Xia Z, Gao F, Gu W, Chen X, Yuan T, Yu H. Inhibition of MAPK/ERK signaling blocks hippocampal neurogenesis and impairs cognitive performance in prenatally infected neonatal rats. *Eur Arch Psychiatry Clin Neurosci*. 2015; 265(6):497–509. [PubMed: 25721317]

- Jickling GC, Liu D, Stamova B, Ander BP, Zhan X, Lu A, Sharp FR. Hemorrhagic transformation after ischemic stroke in animals and humans. *J Cereb Blood Flow Metab.* 2014; 34(2):185–199. [PubMed: 24281743]
- Knecht T, Story J, Liu J, Davis W, Borlongan CV, Dela Pena IC. Adjunctive therapy approaches for ischemic stroke: Innovations to expand time window of treatment. *Int J Mol Sci.* 2017; 18(12)
- La Belle JE, Orozco NM, Paucer AA, Saxe JP, Mottahedeh J, Pyle AD, Wu H, Kornblum HI. Proliferative neural stem cells have high endogenous ROS levels that regulate self-renewal and neurogenesis in a PI3K/Akt-dependant manner. *Cell Stem Cell.* 8(1):59–71.
- Lakhan SE, Kirchgessner A, Hofer M. Inflammatory mechanisms in ischemic stroke: Therapeutic approaches. *J Transl Med.* 2009; 7:97. [PubMed: 19919699]
- Lavrnja I, Parabucki A, Brkic P, Jovanovic T, Dacic S, Savic D, Pantic I, Stojiljkovic M, Pekovic S. Repetitive hyperbaric oxygenation attenuates reactive astrogliosis and suppresses expression of inflammatory mediators in the rat model of brain injury. *Mediators Inflamm.* 2015; 2015:498405. [PubMed: 25972624]
- Lee YS, Chio CC, Chang CP, Wang LC, Chiang PM, Niu KC, Tsai KJ. Long course hyperbaric oxygen stimulates neurogenesis and attenuates inflammation after ischemic stroke. *Mediators Inflamm.* 2013; 2013:512978. [PubMed: 23533308]
- Li J, Liu W, Ding S, Xu W, Guan Y, Zhang JH, Sun X. Hyperbaric oxygen preconditioning induces tolerance against brain ischemia-reperfusion injury by upregulation of antioxidant enzymes in rats. *Brain Res.* 2008; 1210:223–229. [PubMed: 18407255]
- Li JS, Zhang W, Kang ZM, Ding SJ, Liu WW, Zhang JH, Guan YT, Sun XJ. Hyperbaric oxygen preconditioning reduces ischemia-reperfusion injury by inhibition of apoptosis via mitochondrial pathway in rat brain. *Neuroscience.* 2009; 159(4):1309–1315. [PubMed: 19185051]
- Li Y, Dong H, Chen M, Liu J, Yang L, Chen S, Xiong L. Preconditioning with repeated hyperbaric oxygen induces myocardial and cerebral protection in patients undergoing coronary artery bypass graft surgery: A prospective, randomized, controlled clinical trial. *J Cardiothorac Vasc Anesth.* 2011; 25(6):908–916. [PubMed: 21868252]
- Li Z, Liu W, Kang Z, Lv S, Han C, Yun L, Sun X, Zhang JH. Mechanism of hyperbaric oxygen preconditioning in neonatal hypoxia-ischemia rat model. *Brain Res.* 2008; 1196:151–156. [PubMed: 18221732]
- Lim SW, Sung KC, Shiue YL, Wang CC, Chio CC, Kuo JR. Hyperbaric Oxygen Effects on Depression-Like Behavior and Neuroinflammation in Traumatic Brain Injury Rats. *World Neurosurg.* 2017; 100:128–137. [PubMed: 28065873]
- Lim SW, Wang CC, Wang YH, Chio CC, Niu KC, Kuo JR. Microglial activation induced by traumatic brain injury is suppressed by postinjury treatment with hyperbaric oxygen therapy. *J Surg Res.* 2013; 184(2):1076–1084. [PubMed: 23726237]
- Lin H, Chang CP, Lin HJ, Lin MT, Tsai CC. Attenuating brain edema, hippocampal oxidative stress, and cognitive dysfunction in rats using hyperbaric oxygen preconditioning during simulated high-altitude exposure. *J Trauma Acute Care Surg.* 2012; 72(5):1220–1227. [PubMed: 22673248]
- Liu W, Li J, Sun X, Liu K, Zhang JH, Xu W, Tao H. Repetitive hyperbaric oxygen exposures enhance sensitivity to convulsion by upregulation of eNOS and nNOS. *Brain Res.* 2008; 1201:128–134. [PubMed: 18342297]
- Liu W, Liu K, Tao H, Chen C, Zhang JH, Sun X. Hyperoxia preconditioning: The next frontier in neurology? *Neurol Res.* 2012; 34(5):415–421. [PubMed: 22642845]
- Lo EH, Rosenberg GA. The neurovascular unit in health and disease: Introduction. *Stroke.* 2009; 40(3 Suppl):S2–3. [PubMed: 19064779]
- Londahl M. Hyperbaric oxygen therapy as treatment of diabetic foot ulcers. *Diabetes Metab Res Rev.* 2012; 28(Suppl 1):78–84. [PubMed: 22271728]
- Londahl M. Hyperbaric oxygen therapy as adjunctive treatment of diabetic foot ulcers. *Med Clin North Am.* 2013; 97(5):957–980. [PubMed: 23992903]
- Losada DM, Jordani ME, Jordani MC, Piccinato MA, Fina CF, Feres O, Chies AB, Evora PR, de Castro ESO. Should preconditioning hyperbaric oxygenation protect the liver against ischemia-reperfusion injury? An experimental study in a rat model. *Transplant Proc.* 2014; 46(1):56–62. [PubMed: 24507026]

- Lou M, Chen Y, Ding M, Eschenfelder CC, Deuschl G. Involvement of the mitochondrial ATP-sensitive potassium channel in the neuroprotective effect of hyperbaric oxygenation after cerebral ischemia. *Brain Res Bull.* 2006; 69(2):109–116. [PubMed: 16533658]
- Lou M, Eschenfelder CC, Herdegen T, Brecht S, Deuschl G. Therapeutic window for use of hyperbaric oxygenation in focal transient ischemia in rats. *Stroke.* 2004; 35(2):578–583. [PubMed: 14715976]
- Lu KT, Sun CL, Wo PY, Yen HH, Tang TH, Ng MC, Huang ML, Yang YL. Hippocampal neurogenesis after traumatic brain injury is mediated by vascular endothelial growth factor receptor-2 and the Raf/MEK/ERK cascade. *J Neurotrauma.* 2011; 28(3):441–450. [PubMed: 21091268]
- Lu PG, Feng H, Yuan SJ, Zhang RW, Li M, Hu R, Liu ZS, Yin J. Effect of preconditioning with hyperbaric oxygen on neural cell apoptosis after spinal cord injury in rats. *J Neurosurg Sci.* 2013; 57(3):253–258. [PubMed: 23877270]
- Lu PG, Hu SL, Hu R, Wu N, Chen Z, Meng H, Lin JK, Feng H. Functional recovery in rat spinal cord injury induced by hyperbaric oxygen preconditioning. *Neurol Res.* 2012; 34(10):944–951. [PubMed: 23006818]
- Matchett GA, Martin RD, Zhang JH. Hyperbaric oxygen therapy and cerebral ischemia: Neuroprotective mechanisms. *Neurol Res.* 2009; 31(2):114–121. [PubMed: 19298750]
- McDonagh MS, Morgan D, Carson S, Russman BS. Systematic review of hyperbaric oxygen therapy for cerebral palsy: The state of the evidence. *Dev Med Child Neurol.* 2007; 49(12):942–947. [PubMed: 18039243]
- Mendoza-Paredes A, Liu H, Schears G, Yu Z, Markowitz SD, Schultz S, Pastuszko P, Greeley WJ, Nadkarni V, Kubin J, Wilson DF, Pastuszko A. Resuscitation with 100%, compared with 21%, oxygen following brief, repeated periods of apnea can protect vulnerable neonatal brain regions from apoptotic injury. *Resuscitation.* 2008; 76(2):261–270. [PubMed: 17765386]
- Mik EG. Hyperbaric oxygen preconditioning: What remains between hypoxia and hyperoxia? *Clin Exp Pharmacol Physiol.* 2011; 38(10):656–657. [PubMed: 21749437]
- Miljkovic-Lolic M, Silbergleit R, Fiskum G, Rosenthal RE. Neuroprotective effects of hyperbaric oxygen treatment in experimental focal cerebral ischemia are associated with reduced brain leukocyte myeloperoxidase activity. *Brain Res.* 2003; 971(1):90–94. [PubMed: 12691841]
- Milosevic J, Adler I, Manaenko A, Schwarz SC, Walkinshaw G, Arend M, Flippin LA, Storch A, Schwarz J. Non-hypoxic stabilization of hypoxia-inducible factor alpha (HIF-alpha): Relevance in neural progenitor/stem cells. *Neurotox Res.* 2009; 15(4):367–380. [PubMed: 19384570]
- Mu J, Krafft PR, Zhang JH. Hyperbaric oxygen therapy promotes neurogenesis: Where do we stand? *Med Gas Res.* 2011; 1(1):14. [PubMed: 22146131]
- Mu J, Ostrowski RP, Soejima Y, Rolland WB, Krafft PR, Tang J, Zhang JH. Delayed hyperbaric oxygen therapy induces cell proliferation through stabilization of cAMP responsive element binding protein in the rat model of MCAo-induced ischemic brain injury. *Neurobiol Dis.* 2013; 51:133–143. [PubMed: 23146993]
- Napoli E, Lippert T, Borlongan CV. Stem cell therapy: Repurposing cell-based regenerative medicine beyond cell replacement. *Adv Exp Med Biol.* 2018
- Ni XX, Ni M, Fan DF, Sun Q, Kang ZM, Cai ZY, Liu Y, Liu K, Li RP, Xu WG. Heat-shock protein 70 is involved in hyperbaric oxygen preconditioning on decompression sickness in rats. *Exp Biol Med (Maywood).* 2013; 238(1):12–22. [PubMed: 23479759]
- Nie H, Xiong L, Lao N, Chen S, Xu N, Zhu Z. Hyperbaric oxygen preconditioning induces tolerance against spinal cord ischemia by upregulation of antioxidant enzymes in rabbits. *J Cereb Blood Flow Metab.* 2006; 26(5):666–674. [PubMed: 16136055]
- Ostrowski RP, Graupner G, Titova E, Zhang J, Chiu J, Dach N, Corleone D, Tang J, Zhang JH. The hyperbaric oxygen preconditioning-induced brain protection is mediated by a reduction of early apoptosis after transient global cerebral ischemia. *Neurobiol Dis.* 2008; 29(1):1–13. [PubMed: 17822911]
- Ostrowski RP, Jadhav V, Chen W, Zhang JH. Reduced matrix metalloproteinase-9 activity and cell death after global ischemia in the brain preconditioned with hyperbaric oxygen. *Acta Neurochir Suppl.* 2010; 106:47–49. [PubMed: 19812919]
- Ostrowski RP, Stepien K, Pucko E, Matyja E. Hyperbaric oxygen modalities are differentially effective in distinct brain ischemia models. *Med Gas Res.* 2016; 6(1):39–47. [PubMed: 27826422]

- Ostrowski RP, Stepien K, Pucko E, Matyja E. The efficacy of hyperbaric oxygen in hemorrhagic stroke: Experimental and clinical implications. *Arch Med Sci*. 2017; 13(5):1217–1223. [PubMed: 28883864]
- Oyinbo CA. Secondary injury mechanisms in traumatic spinal cord injury: A nugget of this multiply cascade. *Acta Neurobiol Exp (Wars)*. 2011; 71(2):281–299. [PubMed: 21731081]
- Padma MV, Bhasin A, Bhatia R, Garg A, Singh MB, Tripathi M, Prasad K. Normobaric oxygen therapy in acute ischemic stroke: A pilot study in Indian patients. *Ann Indian Acad Neurol*. 13(4):284–288.
- Pan HC, Chin CS, Yang DY, Ho SP, Chen CJ, Hwang SM, Chang MH, Cheng FC. Human amniotic fluid mesenchymal stem cells in combination with hyperbaric oxygen augment peripheral nerve regeneration. *Neurochem Res*. 2009; 34(7):1304–1316. [PubMed: 19152028]
- Peng Y, Feng SF, Wang Q, Wang HN, Hou WG, Xiong L, Luo ZJ, Tan QR. Hyperbaric oxygen preconditioning ameliorates anxiety-like behavior and cognitive impairments via upregulation of thioredoxin reductases in stressed rats. *Prog Neuropsychopharmacol Biol Psychiatry*. 2010; 34(6):1018–1025. [PubMed: 20493230]
- Peng Z, Ren P, Kang Z, Du J, Lian Q, Liu Y, Zhang JH, Sun X. Up-regulated HIF-1 α is involved in the hypoxic tolerance induced by hyperbaric oxygen preconditioning. *Brain Res*. 2008; 1212:71–78. [PubMed: 18439571]
- Perdrizet GA. Preoperative stress conditioning in humans: Is oxygen the drug of choice? *Adv Exp Med Biol*. 2016; 876:223–231. [PubMed: 26782216]
- Perez MF, Ongkeko Perez JV, Serrano AR, Andal MP, Aldover MC. Delayed hyperbaric intervention in life-threatening decompression illness. *Diving Hyperb Med*. 2017; 47(4):257–259. [PubMed: 29241237]
- Pisoschi AM, Pop A. The role of antioxidants in the chemistry of oxidative stress: A review. *Eur J Med Chem*. 2015; 97:55–74. [PubMed: 25942353]
- Ploughman M, Austin MW, Glynn L, Corbett D. The effects of poststroke aerobic exercise on neuroplasticity: A systematic review of animal and clinical studies. *Transl Stroke Res*. 2015; 6(1):13–28. [PubMed: 25023134]
- Qi C, Zhang J, Chen X, Wan J, Wang J, Zhang P, Liu Y. Hypoxia stimulates neural stem cell proliferation by increasing HIF1 α expression and activating Wnt/ β -catenin signaling. *Cell Mol Biol (Noisy-le-grand)*. 2017; 63(7):12–19.
- Qin Z, Song S, Xi G, Silbergleit R, Keep RF, Hoff JT, Hua Y. Preconditioning with hyperbaric oxygen attenuates brain edema after experimental intracerebral hemorrhage. *Neurosurg Focus*. 2007; 22(5):E13.
- Rink C, Roy S, Khan M, Ananth P, Kuppusamy P, Sen CK, Khanna S. Oxygen-sensitive outcomes and gene expression in acute ischemic stroke. *J Cereb Blood Flow Metab*. 2010; 30(7):1275–1287. [PubMed: 20145654]
- Rosignol DA, Rosignol LW. Hyperbaric oxygen therapy may improve symptoms in autistic children. *Med Hypotheses*. 2006; 67(2):216–228. [PubMed: 16554123]
- Sanchez EC. Mechanisms of action of hyperbaric oxygenation in stroke: A review. *Crit Care Nurs Q*. 2013; 36(3):290–298. [PubMed: 23736668]
- Sawada N, Liao JK. Targeting eNOS and beyond: Emerging heterogeneity of the role of endothelial Rho proteins in stroke protection. *Expert Rev Neurother*. 2009; 9(8):1171–1186. [PubMed: 19673606]
- Schulze J, Kaiser O, Paasche G, Lamm H, Pich A, Hoffmann A, Lenarz T, Warnecke A. Effect of hyperbaric oxygen on BDNF-release and neuroprotection: Investigations with human mesenchymal stem cells and genetically modified NIH3T3 fibroblasts as putative cell therapeutics. *PLoS One*. 2017; 12(5):e0178182. [PubMed: 28542481]
- Seyfried J, Wullner U. Inhibition of thioredoxin reductase induces apoptosis in neuronal cell lines: Role of glutathione and the MKK4/JNK pathway. *Biochem Biophys Res Commun*. 2007; 359(3):759–764. [PubMed: 17559804]
- Shams Z, Khalatbary AR, Ahmadvand H, Zare Z, Kian K. Neuroprotective effects of hyperbaric oxygen (HBO) therapy on neuronal death induced by sciatic nerve transection in rat. *BMC Neurol*. 2017; 17(1):220. [PubMed: 29246132]

- Shandley S, Wolf EG, Schubert-Kappan CM, Baugh LM, Richards MF, Prye J, Arizpe HM, Kalns J. Increased circulating stem cells and better cognitive performance in traumatic brain injury subjects following hyperbaric oxygen therapy. *Undersea Hyperb Med.* 2017; 44(3):257–269. [PubMed: 28779582]
- Singhal AB, Benner T, Roccatagliata L, Koroshetz WJ, Schaefer PW, Lo EH, Buonanno FS, Gonzalez RG, Sorensen AG. A pilot study of normobaric oxygen therapy in acute ischemic stroke. *Stroke.* 36(4):797–802. [PubMed: 15761201]
- Shi S, Qi Z, Lou Y, Liu KJ. Normobaric oxygen treatment in acute ischemic stroke: A clinical perspective. *Med Gas Res.* 6(3):147–153.
- Shuvy M, Atar D, Gabriel Steg P, Halvorsen S, Jolly S, Yusuf S, Lotan C. Oxygen therapy in acute coronary syndrome: Are the benefits worth the risk? *Eur Heart J.* 2013; 34(22):1630–1635. [PubMed: 23554440]
- Shyu KG, Hung HF, Wang BW, Chang H. Hyperbaric oxygen induces placental growth factor expression in bone marrow-derived mesenchymal stem cells. *Life Sci.* 2008; 83(1–2):65–73. [PubMed: 18558410]
- Singhal AB, Dijkhuizen RM, Rosen BR, Lo EH. Normobaric hyperoxia reduces MRI diffusion abnormalities and infarct size in experimental stroke. *Neurology.* 2002; 58(6):945–952. [PubMed: 11914413]
- Soejima Y, Hu Q, Krafft PR, Fujii M, Tang J, Zhang JH. Hyperbaric oxygen preconditioning attenuates hyperglycemia-enhanced hemorrhagic transformation by inhibiting matrix metalloproteinases in focal cerebral ischemia in rats. *Exp Neurol.* 2013; 247:737–743. [PubMed: 23537951]
- Soejima Y, Ostrowski RP, Manaenko A, Fujii M, Tang J, Zhang JH. Hyperbaric oxygen preconditioning attenuates hyperglycemia enhanced hemorrhagic transformation after transient MCAO in rats. *Med Gas Res.* 2012; 2(1):9. [PubMed: 22494892]
- Srivastava S, Alfieri A, Siow RC, Mann GE, Fraser PA. Temporal and spatial distribution of Nrf2 in rat brain following stroke: Quantification of nuclear to cytoplasmic Nrf2 content using a novel immunohistochemical technique. *J Physiol.* 2013; 591(14):3525–3538. [PubMed: 23690560]
- Stokum JA, Gerzanich V, Simard JM. Molecular pathophysiology of cerebral edema. *J Cereb Blood Flow Metab.* 2016; 36(3):513–538. [PubMed: 26661240]
- Stonesifer C, Corey S, Ghanekar S, Diamandis Z, Acosta SA, Borlongan CV. Stem cell therapy for abrogating stroke-induced neuroinflammation and relevant secondary cell death mechanisms. *Prog Neurobiol.* 2017; 158:94–131. [PubMed: 28743464]
- Sullivan R, Duncan K, Dailey T, Kaneko Y, Tajiri N, Borlongan CV. A possible new focus for stroke treatment - migrating stem cells. *Expert Opin Biol Ther.* 2015; 15(7):949–958. [PubMed: 25943632]
- Sun L, Marti HH, Veltkamp R. Hyperbaric oxygen reduces tissue hypoxia and hypoxia-inducible factor-1 alpha expression in focal cerebral ischemia. *Stroke.* 2008; 39(3):1000–1006. [PubMed: 18239183]
- Sun L, Xie K, Zhang C, Song R, Zhang H. Hyperbaric oxygen preconditioning attenuates postoperative cognitive impairment in aged rats. *Neuroreport.* 2014; 25(9):718–724. [PubMed: 24870985]
- Sun Y, Liu D, Wang Q, Su P, Tang Q. Hyperbaric oxygen treatment of spinal cord injury in rat model. *BMC Neurol.* 2017; 17(1):128. [PubMed: 28673282]
- Tal S, Hadanny A, Berkovitz N, Sasson E, Ben-Jacob E, Efrati S. Hyperbaric oxygen may induce angiogenesis in patients suffering from prolonged post-concussion syndrome due to traumatic brain injury. *Restor Neurol Neurosci.* 2015; 33(6):943–951. [PubMed: 26484702]
- Tal S, Hadanny A, Sasson E, Suzin G, Efrati S. Hyperbaric oxygen therapy can induce angiogenesis and regeneration of nerve fibers in traumatic brain injury patients. *Front Hum Neurosci.* 2017; 11:508. [PubMed: 29097988]
- Tan JW, Zhang F, Liu HJ, Li Z. Hyperbaric oxygen ameliorated the lesion scope and nerve function in acute spinal cord injury patients: A retrospective study. *Clin Biochem.* 2018; 53:1–7. [PubMed: 29217422]

- Theodoraki K, Tympa A, Karmanioliou I, Tsaroucha A, Arkadopoulou N, Smyrniotis V. Ischemia/reperfusion injury in liver resection: A review of preconditioning methods. *Surg Today*. 2011; 41(5):620–629. [PubMed: 21533932]
- Thom SR. Oxidative stress is fundamental to hyperbaric oxygen therapy. *J Appl Physiol* (1985). 2009; 106(3):988–995. [PubMed: 18845776]
- Thom SR. Hyperbaric oxygen: Its mechanisms and efficacy. *Plast Reconstr Surg*. 2011; 127(Suppl 1): 131S–141S. [PubMed: 21200283]
- Thom SR, Bhopale VM, Velazquez OC, Goldstein LJ, Thom LH, Buerk DG. Stem cell mobilization by hyperbaric oxygen. *Am J Physiol Heart Circ Physiol*. 2006; 290(4):H1378–1386. [PubMed: 16299259]
- Thom SR, Milovanova TN, Yang M, Bhopale VM, Sorokina EM, Uzun G, Malay DS, Troiano MA, Hardy KR, Lambert DS, Logue CJ, Margolis DJ. Vasculogenic stem cell mobilization and wound recruitment in diabetic patients: Increased cell number and intracellular regulatory protein content associated with hyperbaric oxygen therapy. *Wound Repair Regen*. 2011; 19(2):149–161. [PubMed: 21362081]
- Veltkamp R, Siebing DA, Sun L, Heiland S, Bieber K, Marti HH, Nagel S, Schwab S, Schwaninger M. Hyperbaric oxygen reduces blood-brain barrier damage and edema after transient focal cerebral ischemia. *Stroke*. 2005; 36(8):1679–1683. [PubMed: 16020761]
- Venetsanou K, Fildissis G, Tokta R, Brinias C, Baltopoulos G. The role of nitric oxide in cellular response to hyperbaric conditions. *Eur J Appl Physiol*. 2012; 112(2):677–687. [PubMed: 21656226]
- Vince RV, Oliver K, Midgley AW, McNaughton LR, Madden LA. In vitro heat shock of human monocytes results in a proportional increase of inducible Hsp70 expression according to the basal content. *Amino Acids*. 2010; 38(5):1423–1428. [PubMed: 19779802]
- Vlodavsky E, Palzur E, Soustiel JF. Hyperbaric oxygen therapy reduces neuroinflammation and expression of matrix metalloproteinase-9 in the rat model of traumatic brain injury. *Neuropathol Appl Neurobiol*. 2006; 32(1):40–50. [PubMed: 16409552]
- Wada K, Ito M, Miyazawa T, Katoh H, Nawashiro H, Shima K, Chigasaki H. Repeated hyperbaric oxygen induces ischemic tolerance in gerbil hippocampus. *Brain Res*. 1996; 740(1–2):15–20. [PubMed: 8973793]
- Wakai T, Narasimhan P, Sakata H, Wang E, Yoshioka H, Kinouchi H, Chan PH. Hypoxic preconditioning enhances neural stem cell transplantation therapy after intracerebral hemorrhage in mice. *J Cereb Blood Flow Metab*. 2016; 36(12):2134–2145. [PubMed: 26661220]
- Wang F, Wang Y, Sun T, Yu HL. Hyperbaric oxygen therapy for the treatment of traumatic brain injury: a meta-analysis. *Neurol Sci*. 2016; 37(5):693–701. [PubMed: 26746238]
- Wang L, Li W, Kang Z, Liu Y, Deng X, Tao H, Xu W, Li R, Sun X, Zhang JH. Hyperbaric oxygen preconditioning attenuates early apoptosis after spinal cord ischemia in rats. *J Neurotrauma*. 2009; 26(1):55–66. [PubMed: 19196076]
- Wang R, Xu J, Xie J, Kang Z, Sun X, Chen N, Liu L, Xu J. Hyperbaric oxygen preconditioning promotes survival of retinal ganglion cells in a rat model of optic nerve crush. *J Neurotrauma*. 2010; 27(4):763–770. [PubMed: 20070171]
- Wang X, Kang K, Wang S, Yao J, Zhang X. Focal cerebral ischemic tolerance and change in blood-brain barrier permeability after repetitive pure oxygen exposure preconditioning in a rodent model. *J Neurosurg*. 2016; 125(4):943–952. [PubMed: 26824373]
- Wang XL, Yang YJ, Xie M, Yu XH, Liu CT, Wang X. Proliferation of neural stem cells correlates with Wnt-3 protein in hypoxic-ischemic neonate rats after hyperbaric oxygen therapy. *Neuroreport*. 2007; 18(16):1753–1756. [PubMed: 17921881]
- Wang XL, Zhao YS, Yang YJ, Xie M, Yu XH. Therapeutic window of hyperbaric oxygen therapy for hypoxic-ischemic brain damage in newborn rats. *Brain Res*. 2008; 1222:87–94. [PubMed: 18582850]
- Wang Y, Zhang S, Luo M, Li Y. Hyperbaric oxygen therapy improves local microenvironment after spinal cord injury. *Neural Regen Res*. 2014; 9(24):2182–2188. [PubMed: 25657740]

- Wang YC, Zhang S, Du TY, Wang B, Sun XQ. Hyperbaric oxygen preconditioning reduces ischemia-reperfusion injury by stimulating autophagy in neurocyte. *Brain Res.* 2010; 1323:149–151. [PubMed: 20123088]
- Wee HY, Lim SW, Chio CC, Niu KC, Wang CC, Kuo JR. Hyperbaric oxygen effects on neuronal apoptosis associations in a traumatic brain injury rat model. *J Surg Res.* 2015; 197(2):382–389. [PubMed: 25982374]
- Wei L, Fraser JL, Lu ZY, Hu X, Yu SP. Transplantation of hypoxia preconditioned bone marrow mesenchymal stem cells enhances angiogenesis and neurogenesis after cerebral ischemia in rats. *Neurobiol Dis.* 2012; 46(3):635–645. [PubMed: 22426403]
- Wei L, Wang J, Cao Y, Ren Q, Zhao L, Li X, Wang J. Hyperbaric oxygenation promotes neural stem cell proliferation and protects the learning and memory ability in neonatal hypoxic-ischemic brain damage. *Int J Clin Exp Pathol.* 2015; 8(2):1752–1759. [PubMed: 25973064]
- Wei N, Yu SP, Gu X, Taylor TM, Song D, Liu XF, Wei L. Delayed intranasal delivery of hypoxic-preconditioned bone marrow mesenchymal stem cells enhanced cell homing and therapeutic benefits after ischemic stroke in mice. *Cell Transplant.* 2013; 22(6):977–991. [PubMed: 23031629]
- Wetterling F, Chatzikonstantinou E, Tritschler L, Meairs S, Fatar M, Schad LR, Ansar S. Investigating potentially salvageable penumbra tissue in an in vivo model of transient ischemic stroke using sodium, diffusion, and perfusion magnetic resonance imaging. *BMC Neurosci.* 2016; 17(1):82. [PubMed: 27927188]
- Xing C, Arai K, Lo EH, Hommel M. Pathophysiologic cascades in ischemic stroke. *Int J Stroke.* 2012; 7(5):378–385. [PubMed: 22712739]
- Xiong L, Zhu Z, Dong H, Hu W, Hou L, Chen S. Hyperbaric oxygen preconditioning induces neuroprotection against ischemia in transient not permanent middle cerebral artery occlusion rat model. *Chin Med J (Engl).* 2000; 113(9):836–839. [PubMed: 11776082]
- Xiong T, Chen H, Luo R, Mu D. Hyperbaric oxygen therapy for people with autism spectrum disorder (ASD). *Cochrane Database Syst Rev.* 2016; 10:CD010922. [PubMed: 27737490]
- Xu J, Huang G, Zhang K, Sun J, Xu T, Li R, Tao H, Xu W. Nrf2 activation in astrocytes contributes to spinal cord ischemic tolerance induced by hyperbaric oxygen preconditioning. *J Neurotrauma.* 2014; 31(15):1343–1353. [PubMed: 24716787]
- Xue F, Huang JW, Ding PY, Zang HG, Kou ZJ, Li T, Fan J, Peng ZW, Yan WJ. Nrf2/antioxidant defense pathway is involved in the neuroprotective effects of Sirt1 against focal cerebral ischemia in rats after hyperbaric oxygen preconditioning. *Behav Brain Res.* 2016; 309:1–8. [PubMed: 27131779]
- Xue L, Yu Q, Zhang H, Liu Y, Wang C, Wang Y. Effect of large dose hyperbaric oxygenation therapy on prognosis and oxidative stress of acute permanent cerebral ischemic stroke in rats. *Neurol Res.* 2008; 30(4):389–393. [PubMed: 18544257]
- Yamashita S, Hirata T, Mizukami Y, Cui YJ, Fukuda S, Ishida K, Matsumoto M, Sakabe T. Repeated preconditioning with hyperbaric oxygen induces neuroprotection against forebrain ischemia via suppression of p38 mitogen activated protein kinase. *Brain Res.* 2009; 1301:171–179. [PubMed: 19747454]
- Yan W, Fang Z, Yang Q, Dong H, Lu Y, Lei C, Xiong L. SirT1 mediates hyperbaric oxygen preconditioning-induced ischemic tolerance in rat brain. *J Cereb Blood Flow Metab.* 2013; 33(3):396–406. [PubMed: 23299244]
- Yan W, Zhang H, Bai X, Lu Y, Dong H, Xiong L. Autophagy activation is involved in neuroprotection induced by hyperbaric oxygen preconditioning against focal cerebral ischemia in rats. *Brain Res.* 2011; 1402:109–121. [PubMed: 21684529]
- Yang L, Tang J, Chen Q, Jiang B, Zhang B, Tao Y, Li L, Chen Z, Zhu G. Hyperbaric oxygen preconditioning attenuates neuroinflammation after intracerebral hemorrhage in rats by regulating microglia characteristics. *Brain Res.* 2015; 1627:21–30. [PubMed: 26301824]
- Yang Y, Wei H, Zhou X, Zhang F, Wang C. Hyperbaric oxygen promotes neural stem cell proliferation by activating vascular endothelial growth factor/extracellular signal-regulated kinase signaling after traumatic brain injury. *Neuroreport.* 2017; 28(18):1232–1238. [PubMed: 28953090]

- Yang Y, Zhang YG, Lin GA, Xie HQ, Pan HT, Huang BQ, Liu JD, Liu H, Zhang N, Li L, Chen JH. The effects of different hyperbaric oxygen manipulations in rats after traumatic brain injury. *Neurosci Lett*. 2014; 563:38–43. [PubMed: 24412131]
- Yang YJ, Wang XL, Yu XH, Wang X, Xie M, Liu CT. Hyperbaric oxygen induces endogenous neural stem cells to proliferate and differentiate in hypoxic-ischemic brain damage in neonatal rats. *Undersea Hyperb Med*. 2008; 35(2):113–129. [PubMed: 18500076]
- Yang ZJ, Xie Y, Bosco GM, Chen C, Camporesi EM. Hyperbaric oxygenation alleviates MCAO-induced brain injury and reduces hydroxyl radical formation and glutamate release. *Eur J Appl Physiol*. 2010; 108(3):513–522. [PubMed: 19851780]
- Yin D, Zhang JH. Delayed and multiple hyperbaric oxygen treatments expand therapeutic window in rat focal cerebral ischemic model. *Neurocrit Care*. 2005; 2(2):206–211. [PubMed: 16159067]
- Yin D, Zhou C, Kusaka I, Calvert JW, Parent AD, Nanda A, Zhang JH. Inhibition of apoptosis by hyperbaric oxygen in a rat focal cerebral ischemic model. *J Cereb Blood Flow Metab*. 2003; 23(7):855–864. [PubMed: 12843789]
- Yokobori S, Mazzeo AT, Hosein K, Gajavelli S, Dietrich WD, Bullock MR. Preconditioning for traumatic brain injury. *Transl Stroke Res*. 2013; 4(1):25–39. [PubMed: 24323189]
- Yu M, Xue Y, Liang W, Zhang Y, Zhang Z. Protection mechanism of early hyperbaric oxygen therapy in rats with permanent cerebral ischemia. *J Phys Ther Sci*. 2015; 27(10):3271–3274. [PubMed: 26644690]
- Zeng Y, Xie K, Dong H, Zhang H, Wang F, Li Y, Xiong L. Hyperbaric oxygen preconditioning protects cortical neurons against oxygen-glucose deprivation injury: Role of peroxisome proliferator-activated receptor-gamma. *Brain Res*. 2012; 1452:140–150. [PubMed: 22444276]
- Zhai WW, Sun L, Yu ZQ, Chen G. Hyperbaric oxygen therapy in experimental and clinical stroke. *Med Gas Res*. 2016; 6(2):111–118. [PubMed: 27867477]
- Zhang T, Yang QW, Wang SN, Wang JZ, Wang Q, Wang Y, Luo YJ. Hyperbaric oxygen therapy improves neurogenesis and brain blood supply in piriform cortex in rats with vascular dementia. *Brain Inj*. 2010; 24(11):1350–1357. [PubMed: 20715898]
- Zhang XG, Jiang ZL, Wang GH, Li YC, Wang Y, Li X, Shen HM. Therapeutic efficacy of hyperbaric oxygen on traumatic brain injury in the rat and the underlying mechanisms. *Zhongguo Ying Yong Sheng Li Xue Za Zhi*. 2012; 28(1):42–46. [PubMed: 22493893]
- Zhang Y, Bai L, Shi M, Lu H, Wu Y, Tu J, Ni J, Wang J, Cao L, Lei P, Ning X. Features and risk factors of carotid atherosclerosis in a population with high stroke incidence in China. *Oncotarget*. 2017; 8(34):57477–57488. [PubMed: 28915687]
- Zhou HX, Liu ZG, Liu XJ, Chen QX. Umbilical cord-derived mesenchymal stem cell transplantation combined with hyperbaric oxygen treatment for repair of traumatic brain injury. *Neural Regen Res*. 2016; 11(1):107–113. [PubMed: 26981097]
- Zhou JG, Fang YQ, Liu CY, Zhou YQ, Ji YF, Liu JC. Effect of hyperbaric oxygen on the expression of nitric oxide synthase mRNA in cortex after acute traumatic cerebral injury. *Zhongguo Ying Yong Sheng Li Xue Za Zhi*. 2012; 28(1):38–41. [PubMed: 22493892]
- Zhu DY, Lau L, Liu SH, Wei JS, Lu YM. Activation of cAMP-response-element-binding protein (CREB) after focal cerebral ischemia stimulates neurogenesis in the adult dentate gyrus. *Proc Natl Acad Sci U S A*. 2004; 101(25):9453–9457. [PubMed: 15197280]




Figure 1.

A summary of prominent mechanisms of hyperbaric oxygen therapy for pre-stroke, post-stroke, and stem cell preconditioning applications. BBB - blood brain barrier; ICP - intracranial pressure.